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TITLE:   STUDY OF LIPOPROTEIN(A) AND BIOCHEMICAL 
PARAMETERS OF METABOLIC SYNDROME AMONG YOUNGER 
POPULATION.  
INTRODUCTION 
 Metabolic syndrome is defined as the combination of obesity, 
hyperglycemia/diabetes, hypertension and dyslipidemia. Metabolic syndrome is attracting 
more commercial interest, due to components of the MS enhances the chance for cardio 
vascular disease and also the total morbidity and mortality in our population. Lipoprotein (a) 
has emerged nowadays as a powerful genetic risk factor for CAD.  
AIMS AND OBJECTIVES   
Our aim is to know the prevalence of metabolic syndrome among younger population 
and to study the relationship between Lipoprotein (a) and metabolic syndrome. 
MATERIALS AND METHODS 
 Patients and bystanders (136 persons) who attended the medicine OPD of Sree 
Mookambika Institute of Medical Sciences, Kulasekharam, Tamilnadu for routine medical 
check up formed the subjects for the present cross-sectional study. The following 
parameters were collected: age, gender, religion, waist circumference, blood pressure and 
fasting clinical chemistry parameters (Blood glucose, serum triglycerides, HDL and 
lipoprotein (a)).Blood glucose is estimated by GOD-POD method, Serum triglycerides by 
GPO-PAP method, HDL by direct detergent method and lipoprotein (a) by latex turbidimetry 
method. 
 
RESULTS  
 In our study population, prevalence of metabolic syndrome is 47.1% (64 persons) 
according to the Modified NCEP ATP III Criteria and according to the IDF Criteria; 
prevalence is 44.9% (61 persons). Prevalence of metabolic syndrome (By Modified NCEP 
ATP III Criteria or IDF Criteria) with the age category has significant correlation according 
to the p-value 0.000 (<0.01). Amount of lipoprotein (a) is present in the metabolic syndrome 
category, by Modified NECP ATP III Criteria with the mean and standard deviation of 55.65 
± 18.30 and IDF Criteria with the mean and standard deviation of 56.07 ± 18.10. Metabolic 
syndrome category by either Modified NECP ATP III Criteria or IDF Criteria has significant 
correlation with lipoprotein (a) according to their p-value 0.000 (<0.01). 
CONCLUSION 
 Prevalence of metabolic syndrome with age category has significant 
correlation. Prevalence is maximum at the age group of 35-39 years followed by the age 
group of 30-34 years and then 24-29 years.  Lipoprotein (a) level has significant correlation 
with the metabolic syndrome. It has significantly correlated with the individual components 
of metabolic syndrome and age category also (p value <0.01). 
 Key words: Metabolic syndrome, Lipoprotein (a), coronary artery disease. 
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INTRODUCTION 
  A combination of decreasing demands and increased intake of food and 
physical inactivity has led to increasing prevalence of obesity, hyper 
glycaemia/diabetes, hypertension and dyslipidemia.  A combination of all the above 
features is called metabolic syndrome. 1 Increasing prevalence of metabolic syndrome 
in various countries in South Asia, due to rapid nutritional and lifestyle transition in 
urbanized areas.2   
Metabolic syndrome is attracting more commercial interest, due to components 
of the MS enhances the chance for cardio vascular disease and also the total morbidity 
and mortality in our population.3 Different guidelines issued by World Health 
Organization (WHO), National Cholesterol Education Program – Adult Treatment 
Panel III (NCEP-ATP III) and International Diabetes Federation (IDF) have been 
proposed to identify metabolic syndrome in clinical practice.4 
According to WHO estimation 2003, 16.7 million people in the world die due to 
CVD each year and 80% deaths occur in low and middle income countries.5 Asian 
Indians considered to be a “high risk population” for both metabolic syndrome and 
CVD.6  In India, prevalence of metabolic syndrome is varying between 10% to 50% 
depending on age and sex.7  Persons affected with metabolic syndrome have a 30-40% 
chance of developing diabetes and CVD within 20 years, it depends on number of 
individual components present.3 Primordial prevention is the best one to protect the 
adult CVD epidemic.8 For effective prevention of CVD and Type2 diabetes mellitus, 
components of the  MS and obesity recognized early in the lifetime is important.9 
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South Asians have high numbers of diabetes and highest numbers of premature 
CAD in the world, both occur about 10 years early compared to other populations.  
This increased risk is due to South Asian dyslipidemia. It is characterized by high 
levels of apolipoprotein B, lipoprotein (a), triglycerides in the serum and low levels of 
apolipoprotein A1 and HDL cholesterol.10  
Lipoprotein (a) has emerged nowadays as a powerful genetic risk factor for 
CAD.11 Nowadays Clinical interest in Lp(a) has increased more times, because the 
studies  has explained the relationship between plasma Lp(a) concentrations (reported 
as ≥  30mg/dL) and coronary and cerebro vascular disease, peripheral artery disease, 
and also the early origin of atherosclerosis in children and adolescents.  The scarcity of 
studies about the epidemiological behaviour of Lp(a) in our country, the main aim of 
our research is to study the relationship between Lp(a) and the metabolic syndrome and 
its components in younger population .12 
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AIMS AND OBJECTIVES 
1. To know the prevalence of metabolic syndrome among younger population. 
2. To study the relationship between Lipoprotein (a) and metabolic syndrome. 
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REVIEW OF LITERATURE 
EVALUATION OF THE METABOLIC SYNDROME 
In his 1988 lecture Reaven described about the metabolic syndrome. He 
explained that insulin resistance was the main trigger of the syndrome. He named this 
syndrome as syndrome “X”.1 He described the following parameters as the components 
of syndrome “X”- insulin resistance, hyperglycaemia, hyperinsulinemia, increased 
VLDL triglyceride, decreased HDL and hypertension. 13 Reaven had mentioned insulin 
resistance as the central causal factor for the metabolic syndrome, but the more recent 
definitions including International Diabetes Federation (2006) suggested the obesity as 
the central factor for defining the syndrome if at least two other elements of 
hypertension, dyslipidemia and hyperglycaemia are present. So, nowadays insulin 
resistance is not the part of the syndrome.1 
As early as 250 years ago, even before the metabolic syndrome description, the 
Italian anatomist Margagni identified the link between visceral obesity, atherosclerosis, 
HTA (arterial hypertension), frequent respiratory disorders during sleep and the high 
levels of uric acid in the blood.14 
In the year 1920, Nicolae Paulescu, talking about the obesity and diabetes, and 
he said “most frequently, the obese people become glycosuric, as if the two affections 
(obesity and fat diabetes) represent two consequent phases of the same pathological 
process”.15 
In 1927, Maranon, described that arterial hypertension is a pre-diabetical stage 
and this is also similarly applied to obesity. Maranon also explained the fact that food is 
essential for treating and preventing these disturbances. He is a founder of modern 
endocrinology in the Spain. 15 
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In the mid 20th century, the French physician Vague was the first to identify 
‘android obesity’ (upper body adiposity) as the condition most often associated with 
diabetes and cardiovascular disease. 
The often – simultaneous presence of obesity, the high level of blood lipids, 
diabetes mellitus and arterial hypertension was first mentioned under the name of 
Plurimetabolic syndrome in the 1960.  
In the 1970, Moga, Orha, Haragus supported the fact among connection 
between the Metabolic syndrome components at present and correlating that to the 
cardiovascular diseases.13 
The Metabolic syndrome was called by various names in time : the X 
syndrome, the X plus syndrome, the Plurimetabolic syndrome, the X metabolic 
syndrome, the insulin resistance- dyslipidemia syndrome, the cardiovascular metabolic 
syndrome, the syndrome of atherogenic factors’ agglomeration, the atherogenic 
metabolic syndrome, the deadly quartet. Recently, the MetS is used to replace the term 
of metabolic syndrome.16 
DEFINITIONS OF METABOLIC SYNDROME:    There are various definitions 
and cut-off points for defining the metabolic syndrome had proposed. 
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WHO CRITERIA (1999)17 
According to this metabolic syndrome is defined as the presence of  
Diabetes (or) Impaired glucose tolerance (or) Insulin resistance   and ≥ 2 of the 
following parameters: 
(i) BMI         > 30Kg/m2 
WHR       > 0.9 for men,   > 0.85 for women. 
(ii) TG           ≥150 mg/dl (1.7mmol/l) (or)  
HDL-C   <35 mg/dl (0.9mmol/l) for men,     
            <39 mg/dl (1.0mmol/l) for women   
(iii)BP           ≥ 140/90 mmHg or medication 
(iv) Microalbuminuria 
Albumin excretion ≥ 20µgm/min (or) 
Albumin: Creatinine ratio ≥ 30 mg/g 
WHO-World Health Organization    
BMI- Body mass index 
WHR-Waist hip ratio  
TG-Triglycerides   
HDL-C- High density lipoprotein cholesterol  
BP- Blood pressure 
* defined as the top quartile of fasting insulin in the non diabetic population. 
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MODIFIED WHO CRITERIA (MICROALBUMINURIA WAS EXCLUDED) 18 
According to this metabolic syndrome is defined as the presence of  
Diabetes (or) Impaired glucose tolerance (or) Insulin resistance   and ≥ 2 of the 
following parameters: 
(i) BMI         > 30Kg/m2 
WHR      > 0.9 for men,    > 0.85 for women. 
(ii) TG            ≥150 mg/dl (1.7mmol/l) (or)  
HDL-C  <35 mg/dl (0.9mmol/l) for men,     
           <39 mg/dl (1.0mmol/l) for women   
(iii) BP           ≥ 140/90 mmHg or medication 
WHO-World Health Organization    
BMI- Body mass index 
WHR-Waist hip ratio  
TG-Triglycerides   
HDL-C- High density lipoprotein cholesterol  
BP- Blood pressure 
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 EGIR 199918 
According to this, metabolic syndrome is defined as the Insulin resistance * or 
Hyperinsulinemia (only non diabetic subjects) plus 2 or more of the following 
parameters: 
I. Central obesity : waist circumference  ≥ 94cm (M) 
≥ 80cm (F) 
II. Dyslipidemia : Triglycerides    > 2mmol/l (or) 
                          HDL-C              < 1 mmol/l 
III. Hypertension: Blood pressure ≥ 140/90 mm Hg and / or Medication 
IV. Fasting plasma glucose ≥ 6.1mmol/l 
EGIR – European group for the study of insulin resistance 
HDL-C - High density lipoprotein cholesterol 
M – Male 
F – Female  
* defined as the top quartile of fasting insulin in the non diabetic population. 
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NCEP- ATP III CRITERIA19, 20 
 According to this, metabolic syndrome is defined as the presence of ≥ three of the 
following parameters: 
i. Waist circumference    > 102cm in men,  
> 88cm in women 
ii. SBP > 130 mm Hg and /or  
DBP > 85 mm Hg or  
medical treatment of previously diagnosed hypertension. 
iii. TG > 150 mg/dl (1.7mmol/l) 
iv. HDL-C     < 40mg/dl ( 1.0 mmol/l) in men, 
<50mg/dl (1.3 mmol/l) in women 
v. Fasting plasma glucose > 100mg/dl (5.6 mmol/l) changed in 2005 from 110 
mg/dl (6.1 mmol/l). 
NCEP– National Cholesterol Education Program 
ATP III- Adult treatment panel III 
SBP – Systolic blood pressure 
DBP – Diastolic blood pressure 
TG – Triglycerides 
HDL–C – High density lipoprotein cholesterol  
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MODIFIED NCEP- ATP III CRITERIA 10, 21 
According to this, metabolic syndrome is defined as the presence of ≥ three of the 
following parameters: 
i. Waist circumference    ≥ 90cm in men,  
≥ 80cm in women 
ii. SBP                                                     ≥130 mm Hg and /or  
DBP                                                    ≥ 85 mm Hg or  
medical treatment of previously diagnosed hypertension. 
iii. TG                                                     ≥ 150 mg/dl (1.7mmol/l) 
iv. HDL-C     < 40mg/dl ( 1.0 mmol/l) in men, 
<50mg/dl (1.3 mmol/l) in women 
v. Fasting plasma glucose                       ≥ 100mg/dl (5.6 mmol/l)  
NCEP– National Cholesterol Education Program 
ATP III- Adult treatment panel III 
SBP – Systolic blood pressure 
DBP – Diastolic blood pressure 
TG – Triglycerides 
HDL – C – High density lipoprotein cholesterol  
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IDF CRITERIA 22 
According to this, Metabolic syndrome is defined as the presence of central obesity 
(waist circumference
*
 with ethnicity specific values) plus any two of the following 
parameters: 
i. TG ≥ 150mg/dl or specific treatment for this lipid abnormality 
ii. HDL-C    < 40mg/dl (men) 
<50mg/dl (women) 
or specific treatment for this lipid abnormality 
iii. SBP                                        ≥130 mm Hg and /or  
DBP                                         ≥ 85 mm Hg or  
medical treatment of previously diagnosed hypertension 
iv. Fasting plasma glucose ≥100mg/dl or previously diagnosed type 2 diabetes 
mellitus. If >100 mg/dl, OGTT is strongly recommended but is not necessary to 
define presence of the syndrome 
 
IDF – International Diabetes Federation 
SBP – Systolic blood pressure 
DBP – Diastolic blood pressure 
TG – Triglycerides 
HDL – C – High density lipoprotein cholesterol  
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* ETHNIC SPECIFIC VALUES FOR WAIST CIRCUMFERENCE 
1. Europids  
 
In the USA, the ATP III values (102 cm 
male; 88cm females) are likely to 
continue to be used for clinical 
purposes. 
 
Male ≥94cm 
 
Female ≥ 80cm 
2. South Asians 
 
Based on a Chinese, Malay and Asian- 
Indian population 
 
Male ≥90cm 
 
Female ≥ 80cm 
3. Chinese 
Male ≥90cm 
 
Female ≥ 80cm 
4. Japanese 
Male ≥90cm 
 
Female ≥ 80cm 
5. Ethnic south and central Americans Use south Asian recommendations until more specific data are available 
6.  Sub-Saharan Africans Use European data until more specific data are available 
7. Eastern Mediterranean and middle 
East (Arab) populations 
Use European data until more specific 
data are available 
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AACE CRITERIA23 
AACE indroduces a clinical criteria for metabolic syndrome. This criteria seems 
to be a combination of WHO and ATP III MS but here, diagnosis is based on the 
clinical judgement. In patients without Impaired Fasting Glucose (IFG) i.e Fasting 
blood glucose concentration >110 and < 126 mg/dl, glucose challenge test is 
recommended, when an abnormality is clinically suspected. Any abnormal finding in 2 
hour post glucose will improve diagnosis of type 2 diabetes mellitus. 
 
American Association of Clinical Endocrinologists (AACE) criteria for defining  the 
Insulin Resistance Syndrome. 
 
Risk factor components     Cut off  for abnormality 
Overweight/ obesity      > BMI 25kg/m2 
Elevated Triglycerides     > 150 mg/dl (1.69 mmol/l) 
Low HDL Cholesterol  
 Men        <40 mg/dl (1.04 mmol/l) 
 Women       < 50 mg/dl (1.29 mmol/l) 
Elevated blood pressure     > 130/85 mm Hg 
Fasting glucose       Between 110 and 126 
mg/dl 
2 hour post glucose challenge     > 140mg/dl 
14 
 
Other risk factors 
¾ Family history of type 2 diabetes 
¾ Hypertension or Cardiovascular Disease 
¾ Polycystic Ovary syndrome 
¾ Gestational diabetes 
¾ Acanthosis Nigricans 
¾ Sedentary life style 
¾  Advancing age 
¾ Ethnic groups having high risk for type 2 diabetes mellitus or cardiovascular 
disease 
  Diagnosis depends on clinical judgement based on risk factors. 
EPIDEMIOLOGY 
 Data from many world regions suggest that more than 1 in 5 adults have 
metabolic syndrome. It is estimated that 20% to 25% of adults worldwide have 
Metabolic Syndrome. Obesity is widely recognized as one of the biggest health threats 
of the 21st century. 
In a recent review and pooling of literature, it was estimated that 23.2% of the 
world’s adult population in 2005 was overweight (24% of men and 22.4% of women).  
Additionally, 9.8% of the adult population worldwide was obese (7.7% of men and 
11.9% of women). The number of adults projected to be overweight by 2030 is 1.35 
billion with 573 million projected to be obese.24 
 The third NHANES survey showed the prevalence of MS among US adults. 
The age adjusted prevalence of the Metabolic Syndrome was 23.7%. The prevalence 
15 
 
increased from 6.7% in younger participants (20-29 years) to 43.5% (60-69 years) and 
42% (70 years) for older participants. Mexican Americans had highest prevalence of 
the MS (31.9%) and among them women had 26% higher prevalence than men. 
However, among African Americans compared to Mexican Americans, women had 
57% higher prevalence than men.25 
According to ATP III and IDF definitions, the overall prevalence of MetS was 
12.5% and 17.9% respectively in working East African adults (Ethiopia). Using ATP 
III criteria, the prevalence of metabolic syndrome was 10% in men and 16.2% in 
women. Application of the IDF criteria resulted in a metabolic syndrome prevalence of 
14% in men and 24% in women. The most common MetS components among women 
were reduced high density lipoprotein cholesterol (HDL-C) 23.2% and abdominal 
obesity (19.6%); whilst reduced HDL –C concentrations (23.4%) and high blood 
pressure (21.8%) were most common among men.26 
       The metabolic syndrome ratio in the adult turkey population was 17.91%, while 
these ratios for diabetes mellitus and hypertension were 4.16% and 13.66% 
respectively. The prevalence of hypertension, metabolic syndrome and obesity were 
higher in females than males, whereas diabetes mellitus was higher in males than 
females.27 
      It was estimated that 20%-25% of south Asians have developed metabolic 
syndrome and many more may be prone to it. In urban Indian adults aged (20-50 yrs), 
prevalence of metabolic syndrome was reported to be 41.1%.3 
      Nowadays, obesity is increasing epidemically in India. National Nutrition 
Monitoring Bureau depicted the obesity prevalence in Indian women to be 8% and men 
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7%. This is increased compared to the 1990 survey, where the NNMB depicted the 
obesity prevalence in Indian women to be 4.1% and men 2.7%28 and the National 
Family Health Survey documented prevalence rates of obesity  ranging between 3.5%  
to 4.1%.29 
        Today, over 20% of men in urban areas have generalised obesity and about 
women, 40% have abdominal obesity and 30% have generalised obesity.30 It is 
documented that the obesity prevalence in India increased by 89% in males and 82% in 
females between the years of  2002 and 2010.31 
          A study from urban eastern India found the prevalence of metabolic syndrome 
was 43.2% (n=509) and prevalence was higher in females 52.2% (n=307), compared to 
males 34.2% (n=202).39 
            One of the tribal population of India, Bhutia shows higher prevalence of 
metabolic syndrome with no significant rural-urban difference (42.15% in urbanized 
areas, 42.69% in rural areas).32 
            Mohan et al study report shows 18.7% prevalence of insulin resistance 
syndrome in upper socioeconomic class in south India and 6.5% in the lower 
socioeconomic class. The data also shows prevalence of insulin resistance and the 
prevalence of type 2 diabetes are same in rural and urban areas.33 
             In study done in Chennai, prevalence of metabolic syndrome was 46.3% and 
also prevalence of MS increased in males (45%) than the females (42.2%). Among the 
study subjects, 93.2% had one abnormal parameter.34    
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RISK FACTOR CLUSTERING AND PATHOGENESIS 
       The pathogenesis of the metabolic syndrome is multi factorial. The major 
underlying risk factors are obesity and insulin resistance. Risk associated with obesity 
is best identified by increased waist circumference (abdominal obesity), insulin 
resistance can be secondary to obesity but can have genetic components as well. Insulin 
resistance persons with mild to moderate overweight also said to have primary insulin 
resistance. In these persons also weight gain enhances the insulin resistance and 
metabolic syndrome. so, it is difficult to dissociates the  primary insulin resistance and 
obesity in MS patients.    
Several factors further exacerbate the metabolic syndrome: advancing age, 
endocrine dysfunction, physical inactivity, and genetic aberrations altering the 
individual risk factors. The increasing trend of metabolic syndrome prevalence in the 
world is mainly due to obesity exacerbated by the sedentary lifestyles. 
Free fatty acids are produced abundantly from an expanded adipose tissue mass. 
In the liver, it produces an increased production of triglycerides, glucose and secretion 
of VLDL. FFA also causes the reduction in high density lipoprotein cholesterol and an 
increased density of low density lipoproteins. It reduces insulin sensitivity in muscle by 
the mechanism of inhibiting the insulin mediated glucose uptake. Other associated 
defects with this include increased lipid accumulation in triglyceride and a reduction in 
glucose partitioning to glycogen. Increasing the circulating glucose levels and also 
some FFA enhance the production of insulin by pancreas resulting in hyperinsulinemia. 
It may increases the reabsorption of sodium and sympathetic nervous system (SNS) 
activity. Through this mechanism, it contribute to development of the hypertension. 
18 
 
 
                    PATHOGENESIS OF METABOLIC SYNDROME 
          Insulin resistance produced by the excessive FFA levels is superimposed by the 
para and endocrine effect of pro inflammatory state. Adipose tissue produces variety of 
cells including adipocytes, monocyte-derived macrophages, interleukin-6 and tumour 
necrosis factor alpha. Among them, IL-6 and TNF-α results in more insulin resistance 
and lipolysis of triglyceride stores in adipose tissue to circulating FFA. Increased levels 
of IL-6 and other cytokines in the circulation may enhance glucose and VLDL 
production by the liver and insulin resistance in the muscle. Along with production of 
PAI-1 by adipose tissue, Cytokines and FFA also increase the production of fibrinogen 
and PAI-1 by the liver. This will end in a pro-thrombotic state. Reduced levels of 
adiponectin production (insulin sensitizing and anti-inflammatory cytokine) also lead to 
the development and pathophysiology of metabolic syndrome.  
19 
 
COMPONENTS OF THE METABOLIC SYNDROME 35, 36 
ATP III identified six components of the metabolic syndrome related to 
cardiovascular disease. 
• Abdominal obesity 
• Atherogenic dyslipidemia 
• Raised blood pressure 
• Insulin resistance ± glucose intolerance 
• Proinflammatory state  
• Prothrombotic state 
These metabolic syndrome components divide into 3 categories  
¾ Underlying  
¾ Major 
¾ Emerging risk factors. 
• Underlying risk factors for cardiovascular disease are physical inactivity, 
obesity (especially abdominal obesity) and atherogenic diet; the major risk 
factors are hypertension, Low HDL cholesterol, elevated LDL cholesterol, 
family history of premature Coronary heart disease (CHD), cigarette smoking 
and ageing; and the emerging risk factors include insulin resistance, glucose 
intolerance, small LDL particles, elevated triglycerides, Prothrombotic state and 
Proinflammatory state. The later five components are called as metabolic risk 
factors for present purposes. 
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ABDOMINAL OBESITY 
It is the form of obesity, strongly associated with the MS. It clinically presents 
as increased waist circumference.35 Individuals with abdominal obesity, who are not 
obese on the basis of height and weight, also can be insulin resistant.37 
Distinction between large waist circumferences due to increases in visceral fat 
mass or subcutaneous adipose tissue is still debated one. Computed tomography or 
magnetic resonance imaging helps to identifying the distinction between these two.38 
A study provided evidence that visceral adipose tissue has a stronger association 
with MS than abdominal subcutaneous adipose tissue independent of metabolic 
syndrome criteria and measurement site.39 
When there is increases in visceral adipose tissue, expecting more amount of 
free fatty acids to the liver through the splanchnic circulation, whereas increases in the 
level of abdominal subcutaneous fat enhances the lipolysis products into systemic 
circulation and avoid direct effects on hepatic metabolism that means lipid synthesis, 
glucose production  and secretion of prothrombotic proteins (fibrinogen and PAI -1).40 
 These differences in free fatty acid flux explains the increasing waist 
circumference and prevalence of MS in Asians (predominance of visceral fat) 
compared to African- American men (predominance of subcutaneous fat).41, 42 
ATHEROGENIC DYSLIPIDEMIA   
      It manifests in routine analysis of lipoprotein levels by increased triglycerides 
and low HDL levels, but detailed analysis only explains the other lipoprotein 
abnormalities, eg. elevated apolipoprotein B, increased remnant lipoproteins, small 
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LDL and small HDL particles. All the above abnormalities are individually leads to 
atherogenic dyslipidemia.43 
       Increased flux of FFA to the liver causes enhanced production of VLDL in 
general. Action of insulin in the above process is complex one. In normal conditions, 
insulin inhibits the VLDL secretion into the systemic circulation but in the case of 
insulin resistance, increase in FFA flux to the liver increases hepatic triglyceride 
synthesis.44Along with this, it also decreases the  lipoprotein lipase concentrations in 
peripheral tissues mainly adipose tissue. This will result in hypertriglyceridemia. 
Hypertriglyceridemia in insulin resistance is mainly due to increased VLDL secretion 
and some extent by decreased lipoprotein lipase concentrations. 
The second lipid alteration present in the metabolic syndrome is a decreased 
HDL- cholesterol levels. In the presence of hypertriglyceridemia, increased triglyceride 
content and reduced content of the cholesteryl ester in the core of lipoprotein causes the 
formation of small and dense particles.Due to this change in composition of 
lipoprotein, results in enhanced HDL clearance from the circulation. 45, 46 
In addition to HDL, the LDL composition is also altered in a same way. In fact, 
with fasting serum triglyceride more than 2mmol/l, almost  nearly equal to all patients 
have a predominance of small dense LDL.47 This type of change in LDL composition is 
leads to the relative reduction of esterified cholesterol, unesterified cholesterol and 
phospholipid with either an increase or no change in LDL triglyceride.48 
Small dense LDL is more atherogenic compared to buoyant LDL because 
1. It is more toxic to the endothelium. 
2. It is more able to transit through the endothelial basement membrane.  
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3. It adheres well to the glycosaminoglycans. 
4. It has increased susceptibility to oxidation.  
5. It is more selectively bound to scavenger receptors on monocyte derived 
macrophages. 49 
ELEVATED BLOOD PRESSURE 
It highly associates with the obesity and occurs mainly in persons with insulin 
resistance. Hypertension is multifactorial in origin. For example, increasing arterial 
stiffness significantly contributes to systolic hypertension in the elderly.  
The relation between insulin resistance and hypertension is well established. 
Insulin resistance involves glucose but not lipid or potassium metabolism, is located in 
peripheral tissues, but not the liver, is limited to non oxidative pathways of intracellular 
glucose disposal, and is directly correlated with the severity of hypertension.50 The 
relationship between hypertension and insulin resistance relates to several different 
mechanisms. Insulin has the vasodilator activity and secondary effect of reabsorption of 
sodium in the kidney. It also increases the sympathetic nervous system activity.In case 
of insulin resistance, vasodilator property is lost and effect of reabsorption of sodium in 
the kidney. 51, 52, 53 and sympathetic nervous system activity are preserved. 54, 55, 56 
INSULIN RESISTANCE 
It is first identified as the central causal factor for metabolic syndrome. That’s 
why MS is otherwise called insulin resistance syndrome. Even though the mechanism 
of action is uncertain, it mainly correlates with the risk of cardio vascular disease. 
Insulin resistance ends in glucose intolerance that leads to diabetes mellitus which also 
acts as an individual CVD risk factor. 
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Most accepted and unifying hypothesis to describe pathophysiology of 
metabolic syndrome is insulin resistance. Insulin resistance can be defined as a 
condition of decreased responsiveness of these target tissues to normal levels of 
circulating insulin, that is, a state of decreased insulin sensitivity. 57 
Insulin resistance arises from both genetically determined and acquired metabolic 
defects.  
 
In a genetically predisposed individuals, increased amount of circulating FFA 
levels leads to the development of insulin resistance. In the adipose tissue, by the action 
of the enzyme hormone sensitive lipase (cyclic AMP dependant) triglycerides 
converted to free fatty acids. Although the synthesis, manner of secretion, and 
mechanism of endothelial finding of lipoprotein lipase appear similar in all tissues, the 
factors that control gene expression and post translational events related to processing 
vary from tissue to tissue.58 
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Insulin inhibits the action of lipolysis in adipose tissue. In case of insulin 
resistance, this inhibition is lost. So, increased amount of lipolysis and more production 
of free fatty acids occurred in those conditions. Then, excessive FFA inhibits the action 
of insulin. It is mainly by the mechanism of modifying downstream signalling and 
increased substrate availability. 59 
Elevated FFA inhibits insulin signalling. It causes decreases in insulin mediated 
glucose transport in muscle (mediated by a decrease in translocation of GLUT-4). It 
results in muscle glucose transport suppression and decreased glycogen synthesis and 
glycolysis in muscle.60, 61 
PRO-INFLAMMATORY STATE 
 It is mainly identified clinically in persons with metabolic syndrome by the 
increased levels of C-reactive protein. Multiple factors cause elevation of C-reactive 
protein levels. Obesity is among one of them.  
Chronic inflammation may represent a triggering factor in the origin of the 
metabolic syndrome: stimuli such as over nutrition, physical inactivity, and ageing 
would result in cytokine hyper secretion and eventually lead to insulin resistance and 
diabetes in genetically or metabolically predisposed individuals. Alternatively, 
resistance to the anti-inflammatory actions of insulin would result in enhanced 
circulating levels of proinflammatory cytokines resulting in persistent low grade 
inflammation. A generally enhanced adipose tissue derived cytokine expression may be 
another plausible mechanism for the inflammation/metabolic syndrome relationship. 
The role of adipokines (adipose tissue specific or enriched hormones secreted by 
adipose tissue) in the metabolic syndrome is still debated 62, 63 
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Adipokines involved in the inflammation (TNF α, IL-6, IL-8, IL-1β, IL-10, 
Nerve growth factor, Transforming growth  factor-β) and acute-phase response 
(haptoglobin, plasminogen activator inhibitor-1, serum Amyloid A). In case of obesity, 
adipose tissue produces increased amount of these proteins. Through this mechanism, it 
connects with insulin resistance and MS.    
The increases in the levels of inflammatory cytokines including  
• IL- 6 
• TNF α 
• Resistin 
• CRP 
reflect over production by the expanded adipose tissue mass. 64 
 Evidence suggests that monocyte-derived macrophages reside in adipose tissue 
and might be at least in part of the source of the generation of proinflammatory 
cytokines locally and in the systemic circulation.65 There is increasing evidence that 
insulin resistance in the liver, muscle, and adipose tissue is not only associated with the 
abundance of proinflammatory cytokines (and relative deficiency of the anti-
inflammatory cytokine adiponectin), but is a direct result of this burden.66 
 Concentrations of CRP levels vary within ethnic groups and by ethnic origin.67 
For example, concentrations of CRP levels higher in the Asian Indians compared to the  
European whites because of insulin resistance and greater central obesity in our 
peoples.68 
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PROTHROMBOTIC STATE 
 It is characterized by increased plasma plasminogen activator inhibitor (PAI)-1 
and fibrinogen, also associates with the metabolic syndrome.  Fibrinogen, an acute-
phase reactant like CRP, rises in response to a high cytokine state.  Thus, prothrombotic 
and proinflammatory states may be metabolically inter connected.  
 Jones RL and colleagues proposed a hypothetical pathway leading to increased 
plasma fibrinogen level in diabetes. 
Hyperglycemia        Insulin 
resistance 
     Oxidative stress 
 
F1+2         Thrombin 
               Fibrinogen turnover 
 
     Fibrin formation   Fibrinolysis 
 
     Liver    Fragment DD dimer 
                                                           Fibrinogen 
 
       Prothrombotic state 
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  Hyperglycemia and insulin resistance and the consequent oxidative stress may 
give rise to increase thrombin formation.  This process causes increased production of 
prothrombin further leading to prothrombin fragmentation (F1+2) and increased 
turnover of fibrinogen with increased production of fibrin and consequently increased 
release of fragment-D.  Both F1+2 and fragment D regulate production of fibrinogen in 
the liver, increased release of them in the circulation may produce an increase in 
circulating fibrinogen. 
CLINICAL OUTCOMES OF METABOLIC SYNDROME 69, 70 
 ATP III viewed cardio vascular disease as the primary clinical outcome of MS. 
The people affected by the MS have increased chance of getting Type 2 diabetes 
mellitus and CVD. There are two types of risk in people with MS, including short term 
and long term risk. Short term means people affected by MS have increased chance for 
CVD events in the period of less than ten years and drug therapy required for these 
people. Long term means people having less short term risk but increased long term 
risk and life style modification is enough for these patients.  
Cardio vascular disease and all cause mortality are increased in men with the 
metabolic syndrome, even in the absence of base line CVD and diabetes. According to 
the Framingham cohort study, 50% of the population attributable risk for the diabetes 
mellitus is mainly due to metabolic syndrome.35    
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CLINICAL FEATURES AND ASSOCIATED DISEASES 
SYMPTOMS AND SIGNS 
The metabolic syndrome is typically unassociated with symptoms. On physical 
examination, waist circumference may be expanded and blood pressure elevated. The 
presence of one or either of these signs should alert the clinician to search for other 
biochemical abnormalities that may be associated with the metabolic syndrome. Less 
frequently, lipoatrophy or acanthosis nigricans is found on examination, because these 
physical findings are typically associated with severe insulin resistance, other 
components of the metabolic syndrome should be expected. 
CARDIO VASCULAR DISEASE 
 The relative risk for new onset cardio vascular disease in patients with the 
metabolic syndrome, in the absence of diabetes, averages between 1.5 and 3 fold. In an 
8 year follow up of middle aged men and women in the Framingham offspring study 
(FOS), the population attributable risk for patients with the metabolic syndrome to 
develop cardio vascular disease was 34% in men and 16% in women. In the same 
study, both the metabolic syndrome and diabetes predicted ischemic stroke with greater 
risk for patients with the metabolic syndrome than for diabetes alone (19% Vs 7%), 
particularly in women (27% Vs 5%). Patients with metabolic syndrome are also at 
increased risk for peripheral vascular disease. 
TYPE 2 DIABETES 
Overall, the risk for type 2 diabetes in patients with the metabolic syndrome is 
increased three to five fold. It is widely accepted that insulin resistance is an early 
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finding, evident before the onset of hyperglycaemia and predictive of the subsequent 
development of diabetes. The study done by Peter et al showed that Relative risk for 
T2DM is similar in (6.90%) men and women with the MS.167. According to the 
Framingham cohort study, 50% of the population attributable risk for the diabetes 
mellitus is mainly due to metabolic syndrome.35     Non-diabetic patients with MS are at 
a very high risk for the development of diabetes. Risk is particularly high when glucose 
dysregulation is present (impaired fasting glucose or impaired glucose tolerance).  
OTHER ASSOCIATED CONDITIONS 
 In addition to the features specifically associated with metabolic syndrome, 
insulin resistance is accompanied by other metabolic alterations. These included 
elevations in the levels of  apo B and C III, homocysteine, uric acid, prothrombotic 
factors (fibrinogen, PAI-1), asymmetric dimethylarginine, serum viscosity, pro-
inflammatory cytokines, CRP, white blood cell count and  microalbuminuria. Beyond 
cardio vascular disease and type 2 diabetes, individuals with metabolic syndrome 
seemingly are susceptible to other conditions, notably, non-alcoholic fatty liver disease 
(NAFLD) and/or non alcoholic steatohepatitis (NASH), polycystic ovary syndrome 
(PCOD), cholesterol gall stones, asthma, obstructive sleep apnea (sleep disturbances) 
and some forms of cancer. 
NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) 71, 72 
 NAFLD is a spectrum. It has 3 forms of disease (mild, moderate and 
severe).Mild one is simple fatty liver. Moderate one is non-alcoholic steatohepatitis. 
Severe form is cirrhosis. Most extreme form is non-alcoholic fatty liver disease. This 
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condition progresses to the hepato cellular carcinoma or liver failure. Treatment and 
prognosis are different for every condition. 
NAFLD is usually clinically silent, and its impact has mostly under estimated. It 
has minimal and nonspecific symptoms like right upper quadrant discomfort and 
fatigue. Diagnosis is made on incidently by radio graphic findings of fatty liver or 
increased amino transferase levels. 
Non-alcoholic fatty liver disease is closely associated with insulin resistant, 
obesity and metabolic syndrome. Treatment for this condition is treating each 
component of the metabolic syndrome and weight loss. 
POLYCYSTIC OVARY SYNDROME (PCOS) 73, 74 
 Polycystic ovary syndrome is clinically defined as oligomenorrhoea associated 
with hyperandrogenism. It has been described poetically as “the thief of womanhood” 
because women with PCOS seek medical attention for infertility and hirsutism. Many 
patients with polycystic ovary syndrome also have features of the metabolic syndrome, 
including insulin resistance, obesity and dyslipidemia suggesting an increased risk for 
cardio vascular disease. PCOS is highly associated with the metabolic syndrome, with 
prevalence between 40 and 50%. Women with PCOS are 2 to 4 times more chance to 
get MS than the women without PCOS. 
 Insulin resistance is the main causative factor in PCOS affected with metabolic 
syndrome. So, screening for IGT is recommended in adolescent age group itself. First 
line of treatment for PCOS patients is modification of life style and weight reduction 
through enhanced physical activity. More studies are needed to describe the role of 
Insulin sensitizing drugs in PCOS patients with metabolic syndrome. 
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OBSTRUCTIVE SLEEP APNEA (OSA) 75 
 The combination of metabolic syndrome and obstructive sleep apnea (OSA)  
has been referred to as “syndrome Z”. There are many factors to promote the MS in 
OSA patients.Those including alterations in the hypothalamic-pituitary axis, triggering 
of oxidative stress, elevations of many inflammatory mediators (TNF-α, CRP and IL-
6), dysregulation of adipokines levels and sleep deprivation. Knowledge about these 
factors help to prevent the development of metabolic syndrome in OSA patients. 
The number of apneas and hypopneas per hour of sleep is termed the apnea-
hypopnea index (AHI).The diagnosis of OSA can be made when the AHI is more than 
5 in a patient with excessive day time sleepiness.  
 Continuous positive airway pressure (CPAP) treatment in OSA patients 
improves insulin sensitivity.  
HYPERURICEMIA 76, 77  
  Incidence of hyperuricemia in males was 19.07%, which is much higher than 
that in females 3.42%. The pathogenic mechanism may be due to estrogen promoting 
uric acid excretion, so it may be more important for men to prevent hyperuricemia. 
Hyperuricemia is associated with MS components such as dyslipidemia, 
hyperglycemia, obesity, and hypertension. Hyperinsulinemia also decreases the 
excretion of uric acid in the proximal convoluted tubule of the kidney and produces 
hyperuricemia. 
 Microalbuminuria may also be caused by altered endothelial pathophysiology in 
the insulin resistant state.  
32 
 
MANAGEMENT OF METABOLIC SYNDROME 
RISK ASSESSMENT 
 Many approaches are available for estimating the ten year risk for CVD. 
According to the Framingham Heart Study, adding abdominal obesity, triglycerides and 
fasting glucose to Framingham risk algorithm yields little or no increase power of 
prediction; however, in the Quebec Cardiovascular Study, concentrations of fasting 
insulin, triglycerides, apo B, small dense LDL and WC all proved important 
determinants.78 
 The PROCAM (Prospective cardio vascular Munster study) risk algorithm also 
includes a family history of premature coronary heart disease and triglycerides.79 
Increased C-reactive protein levels have high risk for CHD beyond standard 
criteria.80,81 
 According to the Chinese Multi-provincial Cohort Study, original Framingham 
study over estimate the coronary heart disease risk in Chinese population. Recalibration 
is required to correct this over estimation. It also advised to other population with no 
established cohort, to follow the recalibration method.82 
 Metabolic syndrome is common in Indian patients with angiographically 
documented CAD; most patients with Metabolic syndrome have 10-year risk of >10% 
as estimated by FRS (Framingham Risk Score). Though Metabolic syndrome is 
uniformly prevalent across all age groups, using the FRS may underestimate the cardio 
vascular risk in Indian patients despite documented coronary artery disease. These 
findings have significant implications for Asian patients with coronary artery disease in 
whom onset of CAD is often at a younger age than their western counterparts. These 
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shall be continued health care emphasis on detection of metabolic syndrome and 
identification of targeted preventive strategies. 83 
 The FRS may actually underestimate the overall risk in younger patients, who 
are likely to have a longer life expectancy as well as in patients with metabolic 
syndrome. Since CAD often develops at a younger age in the developing world, more 
data are needed on the relationship between metabolic syndrome and FRS in the 
resident Indian population. 
MANAGEMENT OF UNDERLYING RISK FACTORS 
OBESITY 
 It has various definitions according to different population. Management of 
obesity also follow the certain principles. 
 Weight reduction is the best option to reduce all metabolic syndrome risk 
factors. It is mainly achieved by modification of behaviour and enhanced physical 
activity. Through this mechanism, it decreases the energy intake and increases the 
energy expenditure. The first is that “crash diets” and “extreme diets” are seldom 
effective in producing long term weight reduction. Such diets include very low caloric 
diet and high fat/low carbohydrate diets more effective and healthful for long term 
weight loss are reduced energy diets.84, 85 
 Reduced intake of calories, 500-1000 calories per day is adviced to reach a 
weight loss of 0.5-1 Kg per week. The target of reduction of body weight is 7 to 10% 
over one year. Along with this, maintenance of increased physical activity and 
modification of behaviour on long term basis also important. The emphasis in 
behavioural modification should include improvements in eating habits (examples. 
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setting goals, planning meals, reading labels, eating regular meals, reducing portion 
sizes, self monitoring, and avoiding eating binges). Although knowledge and education 
are critical, they are insufficient and thus professional support (Eg. Nutrition 
counselling) is often very helpful. 
 Weight reduction drugs have not been particularly effective for treatment of 
obesity, bariatric surgery is the best option to treat the morbid obesity patients.86 After 
one year follow up in patients undergoing surgery, 95% of them have free from 
symptoms. 87 
In consideration of the safety and advantage of laproscopic bariatric surgery and 
its dramatic effect on the metabolic syndrome, laproscopic bariatric surgery might be 
used more freely in the treatment of the metabolic syndrome. Current indications for 
surgery in morbidly obese patients include body mass index greater than 40 or greater 
than 35 if co-morbidities are present; however, for patients with moderate obesity (BMI 
between30 to 35) and the metabolic syndrome, laproscopic bariatric surgery might be 
included in the choices of treatments.88 
 In addition to resolving the metabolic syndrome, significant weight reduction 
after obesity surgery is also very effective in the reduction of uric acid levels and 
elevated liver function. The significant reduction of white blood cell count after obesity 
surgery reflects the improvement of a proinflammatory state in severely obese patients. 
PHYSICAL INACTIVITY89, 90, 91  
 Physical activity can be characterized by any movement that requires skeletal 
muscles and therefore increases energy expenditure over resting metabolic rate. 
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 Forms of exercise include  
 Aerobic activity 
 Resistance exercise 
        Aerobic exercise consists of rhythmic, repeated and continuous movements of 
the same large muscle for at least 10 minutes at a time. When it is performed at 
sufficient intensity and frequency for several months, maximal oxygen uptake improves 
by 15% - 20% in previously sedentary individuals (Eg. walking, jagging, bicycling and 
swimming). 
          Resistance exercise consists of activities that use muscular strength to move a 
weight or move against a resistive load. By increasing muscle mass and endurance, 
resistant exercise training can produce more rapid changes in functional status and 
body composition than aerobic training. It also improves insulin sensitivity to a similar 
extent as aerobic exercise (Eg. weight lifting and exercise using weight machines).  
           Based on the above data, moderate intensity activity has an important role to 
play in the modification of risk factors for cardio vascular disease and the metabolic 
syndrome. 
ATHEROGENIC AND DIABETOGENIC DIETS92, 93, 94, 95 
 Persons affected by metabolic syndrome must follow the following diet: low 
consumption of simple sugars, reduced intakes of trans fats, saturated fats and 
cholesterol, and high amount of vegetables, fruits and whole grains should be taken. 
Amount of unsaturated fats and carbohydrate intake is still debated. Some investigators 
advised to low fat diet (to promote weight reduction), others advised to take high intake 
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of monounsaturated fat (decreases postprandial hyperglycemia and serum TG levels, 
increases the HDL-C levels). 
 A healthy diet also includes whole grains, fat-free or low fat dairy products and 
protein foods such as lean meats, poultry without skin, seafood, processed soy 
products, nuts, seeds, beans and peas. Choose and prepare foods with little sodium 
(salt). 
 Data suggesting that phytochemical-abundant dietary patterns such as 
Mediterranean diet, may be beneficial for treating metabolic syndrome, because of their 
impact on insulin signalling. 
 Epidemiological studies, particularly in males, suggest that moderate wine 
intake may protect against the development and complications of metabolic syndrome, 
an effect that is at least partially attributable to polyphenols, such as resveratrol, found 
in red wines. 
MANAGEMENT OF METABOLIC RISK FACTORS 
ATHEROGENIC DYSLIPIDEMIA 96, 97, 98, 99, 100 
 This condition consists of increased triglycerides, apo B and small LDL 
particles and low HDL cholesterol. 3-hydroxy 3-methyl glutaryl- coenzyme A 
reductase inhibitors (statins) reduce risk for major cardiovascular disease events in high 
risk patients with the metabolic syndrome by reducing all apo B containing 
lipoproteins. Statins are frequently combined with fibric acid derivatives, to reduce the 
triglyceride and cholesterol levels. Fibrates + statins combination is the popular one, 
but it has higher risk for myopathy. Rhabdomyolysis is a known, rare serious side 
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effect of statin monotherapy and of statin-fibrate combination therapy. It is mainly 
noted for the fibrate Gemfibrozil because this combination produces high statin 
concentrations in the blood. 
  Fenofibrate + Statin combination is less likely to cause myopathy. Low dose of 
nicotinic acid + Statin is an alternative combination to Fibrate + Statin therapy. 
 Bile acid sequestrants like Cholestryamine produce moderate reductions in LDL 
cholesterol. These are second line drugs in atherogenic dyslipidemia and additive in 
LDL cholesterol lowering in combination with other cholesterol lowering drugs. They 
lack systemic toxicity.101 
 Low HDL cholesterol is common among patients managed for dyslipidemia and 
represents an important and under treated source of elevated cardio metabolic risk. 
Nicotinic acid, the most powerful agent currently available for the correction of low 
HDL cholesterol, has been shown in well-designed clinical trials to inhibit the 
progression of atherosclerosis and to reduce cardiovascular event rates in patients at 
high risk of adverse cardiovascular outcome.102 
 Some studies suggest that omega-3 poly unsaturated fatty acids supplementation 
is also effective when added in combination with other lipid-lowering drugs. Omega-3 
fatty acids reduce plasma triglyceride levels by several mechanisms. It can also 
influence the levels of other lipids and lipoproteins including HDL-C and LDL-C.103 
BLOOD PRESSURE104, 105, 106 
 Treatment for patients with hypertension and MS includes two types of therapy, 
pharmacological and non-pharmacological therapy. Non-pharmacological therapy 
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includes   alcohol and calorie restriction, smoking cessation, sodium restriction, 
increased physical activity and weight reduction. 
 Pharmacological therapy includes ACE inhibitors, ARB and central 
sympatholytic agents. Renin Angiotensin Activating system blockers (ACE inhibitors, 
ARB) is the first line of drugs because of their effect of increases the insulin sensitivity 
and sympathetic inhibitory effect. Central sympatholytic agents like Imidazoline 
drugs, are also inhibits the sympathetic nervous system activity.  
ACE inhibitors provide Cardio protective and Reno protective benefits beyond 
their effect on blood pressure: the ARBs also reno protective and cardio protective. 
Long acting calcium channel blockers are recommended in hypertensive patients with 
metabolic syndrome because it produces improvement in insulin resistance. 
Spironolactone along with ACE inhibitor or ARB therapy is the drug of choice for 
diabetic nephropathy patients. 
 Patients with MS require strict blood pressure control.  If type 2 diabetes 
mellitus is present, in 2/3 of them target blood pressure values could be achieved only 
with two or more antihypertensive drugs. 
   Treatment with Irbesartan + hydrochlorothiazide fixed-dose combinations 
provides good blood pressure control in > 2/3 rds of HT patients with metabolic 
syndrome. Lipid and blood pressure targets are reached in a high percentage of patients 
with hypertension and cardio vascular disease treated with a combination of 
Amlodipine + Atorvastatin. 
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INSULIN RESISTANCE AND HYPERGLYCAEMIA107, 108, 109, 110 
 According to previous reports, Metformin or thiazolidinediones decreases the 
type 2 diabetes mellitus risk in IFG/IGT patients but life style intervention is important 
to decreases the risk. 
Czech Diabetes Society provides the latest recommendations, to protect the 
patients suffered by type 2 diabetes mellitus, against coronary and cerebrovascular 
disease is mainly to target all cardiovascular risk factors including Dyslipidemia, 
obesity, hypertension and other symptoms of metabolic syndrome. 
The target HbA1C levels in patients with the low cardiovascular risk should be 
below 4.5% but to target HbA1C below 6%  is enough for the patients with a history of 
limited life expectancy, severe hypoglycaemia, extensive co morbid conditions or 
advanced micro and macro vascular complications or those with long duration diabetes. 
Life style changes are the main aspect of therapy. Metformin is the drug of 
choice. If mono therapy does not provide satisfactory result, combination with other 
oral hypoglycemic agents or insulin provided. 
It is possible to use a range of different combinations, metformin is 
administered with sulphonylurea derivatives (advantage-low price), with a glitazone 
(advantage-no risk of hypoglycaemia), with incretins,acarbose,with glinides, anti 
obesity agents or insulin. The next step is triple combination of hypoglycaemic agents.  
  Therapy also includes dietary and lifestyle changes, and education for 
prevention of complications, particularly prevention of diabetic foot and 
atherosclerosis. 
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 The use of lipid-altering, antihypertensive and hypoglycaemic drugs can modify 
insulin sensitivity and body weight. Metformin and thiazolidinediones improve insulin 
sensitivity but have discrepant effects on body weight; metfomin reduces weight 
whereas thiazolidinediones increase it. The increase in weight in patients treated with 
insulin secretagogues ( sulphonyl ureas and repaglinide or nateglinide) and insulin 
results mostly from improved glyceamic control and increase in caloric intake as a 
result of hypoglycaemia. 
With the exception of nicotinic acid, lipid altering drugs do not affect insulin 
sensitivity or weight, whereas the effect of antihypertensive drugs is more complex. 
Beta adrenergic blockers and thiazide diuretics might decrease insulin sensitivity but 
less so at low doses, whereas ACE inhibitors and angiotensin II receptors antagonists 
have variable effects.  
By uncertain mechanisms, ACE inhibitors and angiotensin II receptors 
antagonists seem to decrease the incidence of type 2 diabetes. 
PROTHROMBOTIC STATE 
Metabolic syndrome is accompanied by elevation in Prothrombotic factors 
(fibrinogen, plasminogen activator inhibitor 1 and possibly other coagulation factors). 
The only available clinical approach to an increased risk for arterial thrombosis in 
patients with metabolic syndrome is low dose asprin or other antiplatelet drugs. These 
drugs are universally recommended unless contraindicated in patients with established 
cardiovascular disease. In other people with the metabolic syndrome, asprin 
prophylaxis is a therapeutic option when the risk for cardiovascular disease events is 
judged to be relatively high.  
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Assessment of prothrombotic state typically found in subjects with metabolic 
syndrome is not so easy in routine medical laboratory. The level of fibrinogen can be 
easily determined automatically, however, coagulation factors such as plasminogen 
activator inhibitor 1 are generally not routinely measured. 
Weight loss due to lifestyle modifications such as low caloric diet, physical 
activity, and adequate pharmacologic interventions influencing simultaneously single 
components of the metabolic syndrome (antihypertension, antidiabetic, hypolipemic 
and antithrombotic agents) are effective methods to decrease the impact of 
prothrombotic state in metabolic syndrome and it can prevent the development of 
atherothrombosis and its clinical manifestations. 
PROINFLAMMATORY STATE 
  This state is characterized by increased levels of cytokines and acute phase 
reactants. Among this increased levels of CRP concentrations is the main indicator of 
proinflammatory state and it has high risk for diabetes and CVD.111 
 Life style therapies, mainly weight reduction, decreases the C-reactive protein 
levels and also the inflammatory state. Some study demonstrates that during weight 
loss, after gastric restrictive surgery, inflammatory mediators remain elevated for 
atleast 3 months postoperatively, suggesting initially an ongoing inflammatory state. 
However, 2 year after surgery,the inflammatory mediators reach near normal values.112 
 No specific anti-inflammatory drugs are available to treat the proinflammatory 
state. However, several drugs used to treat other metabolic risk factors- statins, fibrates 
and thiazolidinediones have been reported to reduce concentrations of C- reactive 
proteins.113 
42 
 
THERAPEUTIC STRATEGY FOR METABOLIC SYNDROME: 
primary goals of therapy (recommended) →secondary goals (informed by clinical 
judgement) 
RISK FACTOR 
(10 yr risk for 
coronary heart 
disease) 
Lower to moderate 
risk (<10%) 
Moderately high 
risk (10-20%) 
High risk (>20%)* 
Metabolic 
syndrome as a 
whole 
Reduce lifetime risk 
for ASCVD and 
diabetes 
Reduce both  
lifetime and short -
term risk 
Reduce short- term 
risk 
Obesity  
 
10% reduction in 
body weight 
(preference to 
lifestyle therapy) 
→BMI <25% 
10% reduction in 
body weight 
(consider weight 
loss drugs) →BMI 
<25% 
10% reduction in 
body 
weight(consider 
weight loss drugs) 
→BMI <25% 
Atherogenic diet 
 
Maximal anti- 
atherogenic diet 
Maximal anti- 
atherogenic diet 
Maximal anti- 
atherogenic diet 
Physical inactivity 
 
Exercise 30 
min/day→60 
min/day 
Exercise 30 
min/day→60 
min/day 
Exercise 30 
min/day→60 
min/day 
Atherogenic 
dyslipidemia : 
↑LDL cholesterol 
(non-HDL 
cholesterol) 
LDL cholesterol 
(non-HDL 
cholesterol)<130 
(160) mg/dl→100 
(130) mg/dl (with 
lifestyle) 
LDL cholesterol 
(non-HDL 
cholesterol)<130 
(160) mg/dl (with 
drugs if 
necessary)→100 
(130) mg/dl  
LDL cholesterol 
(non-HDL 
cholesterol)<100 
(130) mg/dl→70 
(100) mg/dl (in 
CHD patients) 
Atherogenic 
dyslipidemia:  
↓ HDL cholesterol 
Raise HDL 
(lifestyle therapy) 
Raise HDL 
(lifestyle therapy) 
Raise HDL 
(consider drug  
therapy) 
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Blood pressure 
 
BP <140/90 mmHg 
(with drugs if 
necessary)→130/80 
(with lifestyle 
therapies) 
BP <140/90 mmHg 
(with drugs if 
necessary)→130/80 
(with lifestyle 
therapies) 
BP <140/90 mmHg 
(with drugs if 
necessary)→130/80 
(with drugs in 
diabetes and chronic 
renal failure) 
Elevated fasting 
blood sugar 
(prediabetes) 
FBG<100 mg/dl 
(with lifestyle 
therapy) 
FBG<100 mg/dl 
(with lifestyle 
therapy) 
FBG<100 mg/dl 
(consider insulin 
sensitizer) 
Elevated fasting 
blood sugar 
(diabetes) 
HbA1C  6-7% HbA1C  6-7% HbA1C  6-7% 
Prothrombotic 
state 
 
No drug Consider anti 
platelet drug 
(aspirin) 
Anti platelet drug 
(aspirin) 
Proinflammatory 
state 
Complete smoking 
cessation 
Complete smoking 
cessation 
Complete smoking 
cessation 
 
*High risk patients include those ASCVD, diabetes, and those multiple risk factors and 
10-yr risk for coronary heart disease greater than 20%. 
LIPOPROTEINS AND ITS METABOLISM 
Lipoproteins are complexes of lipids and proteins that are essential for the 
transport of cholesterol, triglycerides and fat-soluble vitamins.114 
COMPOSITION OF LIPOPROTEIN 
Lipoproteins are complex macromolecular spherical complexes that contain 
hydrophobic non- polar lipids (triglycerides, cholesteryl esters and fat soluble vitamins) 
surrounded by hydrophilic lipids (phospholipids, unesterified cholesterol) and proteins 
that interact with body fluids .114,115,116,117 Free cholesterol molecules are dispersed 
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throughout the lipoprotein shell to stabilize it in a way that allows it to maintain its 
spherical shape.117 The association of the core lipids with the phospholipids is 
noncovalent, occurring primarily through hydrogen bonding and van der Waal’s forces. 
This binding is loose enough to allow ready exchange of lipids among the plasma 
lipoproteins and between cell membranes and lipoprotein, yet strong enough to allow 
the various classes and subclasses of lipoproteins to be isolated by a variety of 
analytical techniques.116 
 
Structure of Lipoprotein 
 
 
 
The lipoproteins are essential mainly for the transport of water insoluble lipids 
through the aqueous blood plasma.115 Lipoproteins play an essential role in the 
absorption of dietary cholesterol, long chain fatty acids and fat soluble vitamins, the 
transport of triglycerides, cholesterol and fat soluble vitamins from the liver to the 
peripheral tissues and the transport of cholesterol from the peripheral tissues to the 
liver.114 
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CLASSIFICATION OF LIPOPROTEINS 
The plasma lipoproteins are divided into five major subclasses based on their 
relative density as determined by ultracentrifugation.114, 115 
i. Chylomicrons 
ii. Very low density lipoproteins 
iii. Low density lipoproteins 
iv. Intermediate density lipoproteins 
v. High density lipoproteins 
Each lipoprotein class comprises a family of particles that vary slightly in 
density, size and migration during electrophoresis and protein composition. The density 
of lipoprotein is determined by the amount of lipids per particle. HDL is the smallest 
and the most dense lipoprotein while chylomicrons and VLDL are the largest and least 
dense lipoproteins. Most plasma triglycerides are transported by chylomicrons and 
VLDL while cholesteryl esters are transported by LDL and HDL.114 
The physico-chemical properties are summarized in the table below: 118 
Lipoproteins 
Chylomicr
ons 
VLDL IDL LDL HDL 
Density(g/ml) <0.95 0.95-1.006 1.006-1.019 
1.019 -
1.063 
1.063-
1.210 
Electrophoretic 
Mobility 
Origin pre-β 
Between β 
and pre-β 
Beta β Alpha α 
Molecular 
weight 
(Daltons) 
0.4-
30X109 
5-10x106 3.94.8X106 2.75X106 
1.83.6 X 
105 
Diameter (nm) >70 25-70 22-24 19-23 4-10 
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Lipid Protein 
ratio 
99:1 90:10 85:15 80:20 50:50 
Major lipids 
Exogenous 
TG 
Endogenous 
TG 
Endogenous 
TG & 
Cholesterol 
esters  
Cholesterol 
esters 
Phospho 
lipids 
Major Proteins 
A1, B48, 
CI, CII, 
CIII 
B100, CI,  
CII, CIII, E 
B-100,E B-100  AI,AII 
Triglycerides 80-95 55-80 20-50 5-15 5-10 
Cholesterol 2-7 5-15 20-40 40-50 15-25 
Phospholipids 3-9 10-20 15-25 20-25 20-30 
Proteins 1-2 7-10 11 21 50 
 
APOLIPOPROTEINS (APOPROTEINS) 
The proteins or polypeptides associated with lipoproteins are called as 
apolipoproteins.114, 115,116,117 
 Ten principle apoproteins are characterized.117 One or more apoproteins are 
present in each lipoprotein. The major apolipoproteins of HDL is designated A. The 
main apolipoprotein of LDL is ApoB100, which is also found in VLDL. Chylomicrons 
contain a truncated form of apoB (B-48), which is synthesized in the intestine while 
apoB100 is synthesized in the liver. ApoC-I, C-II and C-III are freely transferable 
between several lipoproteins. Apo E is found in VLDL, HDL, chylomicrons and 
chylomicron remnants.115 
Apolipoproteins collectively have three major functions116 
1. Activating important enzymes in the lipoprotein metabolic pathways. 
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2. Maintaining the structural integrity of the lipoprotein complex. 
3. Facilitating the uptake of lipoprotein into cells through their recognition by 
specific cell surface receptors.  
Lipoprotein Metabolism 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
48 
 
EXOGENOUS PATHWAY (DIETARY LIPIDS) 
Dietary lipids are hydrolyzed by lipases within the intestinal lumen and 
emulsified with bile acids to form micelles. Dietary cholesterol, fatty acids and 
fatsoluble vitamins are absorbed from the proximal small intestine. Cholesterol and 
retinol are esterified, long chain fatty acids are incorporated into triglycerides and they 
are packaged with B48, phospholipids and cholesterol in the golgi apparatus to form 
chylomicrons. The nascent chylomicrons are carried via the intestinal villi to intestinal 
lymph and delivered via the thoracic duct directly into systemic circulation. Shortly 
after entering circulation, the particles acquire C apolipoproteins and apo E from 
circulating HDL. Apo CII present on the chylomicrons now activates the enzyme 
Lipoprotein lipase (LPL), anchored to the proteoglycans present on the capillary 
endothelial surfaces of adipose tissue, heart and skeletal muscle. The LPL rapidly 
hydrolyses the triglycerides to free fatty acids, which are taken up by muscle cells as an 
energy source or into adipose cells for storage by re-esterification into triglycerides. 
Some of the fatty acids bind albumin and is transported to other tissues. The 
chylomicron particle progressively shrinks in size as the hydrophobic core is 
hydrolyzed and the hydrophilic lipids and the apoproteins on the particle surface are 
transferred to HDL, creating chylomicron remnants. The chylomicron remnants are 
rapidly taken up by liver by endocytosis for which the apoE acts as a ligand for the 
receptor. It is then hydrolyzed by the lysosomes. The cholesterol released can form bile 
acids, be incorporated into newly synthesized lipoprotein or be stored as cholesteryl 
esters. It can also down-regulate HMG Co-A reductase, the rate- limiting enzyme in 
cholesterol synthesis.114 ,115 
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Exogenous pathway – metabolic fate of Chylomicrons 119 
 
 
ENDOGENOUS PATHWAY (HEPATIC LIPIDS)  
The endogenous pathway of lipoprotein metabolism refers to the hepatic 
secretion of apoB-containing lipoprotein and its metabolism. The hepatocytes 
synthesize triglycerides from fatty acids and carbohydrates. Cholesterol is acquired 
from receptor mediated uptake of chylomicron remnants and also de-novo synthesis of 
cholesterol by up-regulation of HMG Co-A reductase. The triglycerides and cholesterol 
along with apoproteins is packaged into secretory vesicles in the golgi apparatus, which 
requires microsomal transfer protein (MTP) 114, exocytosed into the extracellular space 
and introduced into circulation through the fenestrae of hepatic sinusoidal endothelium 
in the form of nascent VLDL. This triglyceride rich particle (55% by mass) contains 
apoB100, apoE and small amounts of C apoproteins on its surface. After secretion into 
the plasma, VLDL acquires multiple copies of apoE and C apolipoproteins by transfer 
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from HDL. In circulation, the triglycerides in VLDL are hydrolyzed by LPL, especially 
in muscle and adipose tissue. During the hydrolysis, the C apolipoproteins are 
transferred back to HDL. VLDL particles are thus converted to VLDL remnants, some 
of which are taken up by the liver and the rest are converted to smaller, denser particles 
called IDL. The IDLs contain roughly equal amounts of cholesterol and triglycerides. 
The liver removes approximately 40-60% of IDL by LDL receptor mediated 
endocytosis via binding to apoE. The remainder of IDL is remodelled by hepatic lipase 
(HL) to form LDL. During this process, most of the triglycerides in the particle is 
hydrolyzed, all apolipoproteins except apoB100 are transferred to other lipoproteins. 
The cholesterol in LDL accounts for over half of the plasma cholesterol in most 
individuals. Approximately 70% of circulating LDL is cleared by LDL receptor 
mediated endocytosis in the liver.114 
  
Endogenous pathway-Metabolic fate of VLDL and production of LDL  
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LOW-DENSITY LIPOPROTEIN RECEPTOR PATHWAY 
LDL receptors are specific receptors present in coated pits on plasma 
membranes that recognize and bind apoB100 of LDL. When LDL binds to the receptor, 
it is internalized by endocytosis. The acidic milieu of the endosome dissociates the 
receptor from the LDL and the receptor returns to the cell surface while LDL migrates 
to the lysosome. Here, apoB100 is degraded to small peptides and amino acids. 
Cholesteryl esters are hydrolyzed and the cholesterol is utilized for the synthesis cell 
membrane, steroid hormone and bile acids where appropriate. Oversupply of free 
cholesterol leads to:  i. Inhibition of HMG Co-A reductase. ii. Increased cholesteryl 
ester formation by ACAT and iii. Inhibition of new LDL synthesis. LDL remains in 
circulation for about 3 days. LDL is also taken up by extrahepatic tissue (Eg. 
macrophages) through the scavenger receptors or non-receptor mediated pinocytosis. 
Macrophages that become engorged with cholesteryl esters are called “foam cells" 
which are the earliest lesions of atherosclerosis. Two thirds of the LDL is normally 
removed by LDL receptors and the remainder by scavenger cell system.114 
HIGH DENSITY LIPOPROTEIN REVERSE CHOLESTEROL TRANSFER 
PATHWAY 
This pathway transports excess cholesterol from the periphery back to the liver 
for excretion. HDL is secreted from the liver and the intestine as disk shaped nascent 
particles that consist primarily of phospholipids and apoA1. Newly secreted apoA-1 
rapidly acquires phospholipids and unesterified cholesterol from its site of synthesis via 
efflux promoted by the membrane protein ATP-binding cassette protein A1 (ABCA1) 
resulting in the formation of discoidal HDL particles which further acquire unesterified 
cholesterol from the periphery. The acquired cholesterol is esterified by Lecithin- 
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Cholesterol Acyl Transferase (LCAT), a plasma enzyme associated with HDL and the 
more hydrophobic cholesteryl esters moves to the core of the HDL particles. The HDL 
particles progressively becomes spherical and adds on to further lipids and apoproteins 
transferred from the surfaces of chylomicrons and VLDL during lipolysis. HDL 
cholesterol can be selectively taken up by the liver via selective transfer of lipids to 
cells. HDL apoE can also be recognized by the hepatic remnant receptors. HDL 
cholesteryl  esters can also be transferred to apoB containing lipoproteins in exchange 
for triglyceride by the Cholesterol Ester Transfer Protein (CETP).114,116 
 HDL particles undergo extensive remodelling in the plasma by a variety of 
lipid transfer proteins and lipases. Phospholipid transfer protein transfers phospholipids 
from other lipoproteins to HDL. After CETP- mediated lipid exchange, the triglyceride 
enriched HDL becomes a much better substrate for Hepatic lipase (HL) which 
hydrolyses the triglycerides and phospholipids to generate smaller HDL particles that 
are catabolised faster.114 
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HDL reverse cholesterol pathway - Metabolism of HDL120 
 
 
 
 
 
 
 
 
 
 
 
 
LIPOPROTEIN (a) 
Lipoprotein (a) is also called as the sinking pre-β-lipoprotein is similar to LDL 
in its protein composition.121 Lp(a) is a complex particle in human plasma that is 
assembled from one LDL molecule that carries all the lipid and one glycoprotein 
[apo(a)], which has a high degree of homology to plasminogen.122,123 
HISTORICAL ASPECTS 
Lp(a), was discovered by Ka¨re Berg 124,125,126(1963) in Norway in a 
immunochemical study designed to detect antigenic variations in human LDL.122 Lp(a) 
was purified to homogeneity and characterized in some detail in the early 1970s. Lp(a) 
was rediscovered several times and designated “Pre-beta-1 lipoprotein”.124,125,127 Harvie 
and Schultz reported that their preparations of Lp(a) had a rather broad sedimentation 
coefficient distribution, and suggested heterogenicity of Lp(a). The first systematic 
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study on Lp(a) heterogeneity was carried out in 1984 by Fless et al., who not only 
confirmed the findings of Harvey and Schultz but also found that Lp(a) exhibits both 
inter- and intra-individual density heterogeneity, and that this heterogeneity is 
accounted for by differences in lipid and protein composition. Scanu et al. and Fless et 
al. in 1990 first established that the protein moiety of Lp(a), namely the apo B-apo(a) 
complex contrary  to apoB100, is water soluble.128 
A breakthrough in Lp(a) research was the cloning and sequencing of apo(a) by 
MC Lean et al(1986), which revealed a high degree of homology of apo(a) with 
plasminogen.127 Discovery of the genetic size polymorphism of apo(a) by Utermann et 
al. (1987) has provided major insights into the genetic control of plasma Lp(a) 
concentrations.128 As early as 1967 Renninger et al. recognized a positive association of 
Lp(a) lipoprotein with myocardial infarction.129 The clinical interest in Lp(a) arose 
when Dahlen and co-workers recognized a higher frequency of Lp(a) positive subjects 
among men with coronary heart disease as compared with the controls.125,127 
STRUCTURE OF Lp(a) 
Lp(a) is LDL-like particle formed by the association of the highly polymorphic 
glycosylated apolipoprotein(a) (apo(a)) with apolipoprotein B100 (apo B100), the 
classic protein moiety of LDL. The apo(a) is attached to apo B100 through a single 
disulphide link between apo B100 Cys 3734 and apo(a) kringle(K) IV type 9 Cys122; 
additional noncovalent interactions play accessory roles in promoting, mediating and 
reinforcing the association between the apolipoproteins. Under microscopic analysis of 
Lp(a) particles, apo(a) assumes a belt-like structure; both apo(a) ends are attached at 
two distant sites to a spherical LDL.130 
 
55 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Schematic model of the structure of human plasma Lp(a). Lp(a) is made up of an LDL-like 
structure in which apo B100, the protein moiety of authentic LDL, is covalently linked to a 
glycoprotein, apo(a), which is the specific marker of Lp(a) and exhibits a striking similarity to 
plasminogen. The dominant structural motif of apo(a) is the "kringle," a three-disulfide, triple 
loop structure named for its resemblance to a Danish pretzel. K4 is repeated 13-37 times, 
whereas there is only one kV. It is now established that the size of each apo(a) isoform is under 
strict genetic control and determined by the number of kringles that it contains. Usually, there is 
1 mol of apo(a) and I mol of apo B100 in each Lp(a) particle. However, species of Lp(a) having 
one copy  of apo B100 and 2 mol of apo(a) have been reported)128 
 
STRUCTURE OF Apo(a) 
Apo(a) is a high molecular weight glycoprotein with a high carbohydrate 
content and displaying remarkable size heterogeneity. Several molecular weight forms 
have been described with masses ranging from 280000 to 700000 daltons. The genetic 
basis for this polymorphism is due to six different apo(a) phenotypes. It has been 
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postulated that apo(a) phenotypes are controlled by a series of autosomal alleles at a 
single locus.131 The complete primary amino acid sequence of an apo(a) of unknown 
phenotype has been recently derived by sequencing cloned human apo(a) cDNA. Initial 
protein sequencing studies had revealed a high degree of homology between peptides 
from apo(a) and human plasminogen.123,131 The latter is a single-chain protein of Mr 
92000 containing several distinct structural regions: an N-terminal sequence of 76 
amino acids is followed by five tandemly arranged kringle domains having 
approximately 40%-50% homology with each other. Each kringle contains 78-80 
amino acids and includes six Cys residues with disulfide bridges between the first and 
sixth, second and fourth, and third and fifth cysteines in each kringle sequence, giving 
it a characteristic triple-loop structure. Sequencing of apo(a) at the protein level had 
revealed a high degree of homology with plasminogen.131 Plasminogen is a plasma 
serine protease of the fibrinolytic system.126 Apo(a) contains one copy each of 
sequences homologous to the kringle V and protease regions from plasminogen.123,131 
Apo(a) is much larger than plasminogen. This is due to the amplification of one of the 
plasminogen like K IV in apo(a). There are ten distinct classes (subtypes) of Kringle IV 
that differs from each other in amino acid sequence copy. Subtypes 1 and 3 to 10 are 
present in a single copy. Subtype 2 is present in variable numbers (3 to >40). This is 
responsible for the size heterogeneity of apo(a) . In contrast to plasminogen, apo(a) has 
a high carbohydrate content. During protein sequencing studies, a carbohydrate-rich 
peptide was isolated in high yield, which could be separated from the other apo(a) 
peptides by gel filtration alone. This peptide Tl was 55 amino acids in length. This 
peptide represents the sequence connecting two kringle IV-like domains. Seven 
probable glycosylation sites could be identified in peptide Tl: one N-linked 
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oligosaccharide within the kringle and six O-linked oligosaccharides (four Thr and two 
Ser) in the connecting sequence.131 
 
Structural Comparison between Human Plasma Apo(a) and 
Plasminogen132 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*      Apo(a): -Met-Glu-His-Lys-Glu-Val-Val-Leu-Leu-Leu-Leu-Leu-Phe-Leu-Lys-Ser-
Ala-Ala-Pro 
 
**    Plasminogen: -Met-Glu-His-Lys-Glu-Val-Val-Leu-Leu-Leu-Leu-Leu-Phe-Leu-Lys- 
 Ser-Gly-Gln-Gly-. .. 
 
***  Isoforms with higher or lower K4 number are possible 
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CHARACTERISTICS OF Lp(a) 
Lp(a) 
Electrophoretic mobility 
(agarose)  
Pre – beta 
Buoyant density(g/ml)  1.040-1.131 
Isoelectric Point(pl) 4.9 
Molecular mass (Daltons) 3.8-4.66x106 
Molecular diameter(A0) 250 
Plasma concentration (mg/dl) 0.1 to 120 
Protein(g/ml)  800000-1350000 
Free cholesteryl ester (mol/mol)  750 
Cholesteryl ester (mol/mol) 2000 
Triglycerides (mol/mol) 350 
Phospholipids (mol/mol) 1110 
Fractional catabolic rate 
(per day) 
0.26-0.306 
Plasma t1/2 days 3.32-3.93 
Synthetic rate (mg/kg/day) 4.60+/-3.64(0.54-11.39) 
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METABOLISM OF Lp (a) 
Apo(a) transcripts have recently been found in adrenal glands, lungs, pituitary, 
brain and testes, circulating apo(a) is mainly synthesized by the liver as a precursor 
with lower molecular mass which is processed into the mature form and then secreted 
into the blood stream.130 
Rapidly after secretion, free apo(a) binds to circulating LDLs to generate 
complete Lp(a) particles. The association between apo(a) and apo B occurs 
extracellularly following secretion rather than inside cellular compartments since 
coprecipitation of apo B and apo(a) was only observed in the culture medium and not in 
cell lysates.123,130 Specific kringle-4 domains in apo(a), mainly T-6 and T-7, bind in a 
first step to circulating LDL, followed by the stabilization of the newly formed Lp(a) 
complex by a disulfide bridge.133 The apo(a)/ Lp(a) secretion from hepatocytes is 
regulated at various levels including postranslationally by apo(a) isoform-dependent 
prolonged retention in the endoplasmic reticulum.134 
   About 90% of Lp(a) concentration is under genetic regulation.130 Lp(a) levels 
are particularly affected by apo(a) synthetic rate, which is subject to strong genetic 
regulation. The greatest part of the variability in Lp(a) levels (over 40%) is accounted 
for by quantitative polymorphism in the internal sequence of the apo(a) gene; 
qualitative polymorphisms in the sequence of the promoter play only a minor role 
(from 10 to 14%)0.130 Despite this genetic regulation, some metabolic abnormalities 
which may have an effect on Lp(a) levels in the plasma are the diabetes, liver and renal 
failure, acute-phase response, hormonal homeostasis and defects in the LDL-receptor 
gene have all been shown to influence the still enigmatic metabolism of this 
lipoprotein.130 
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 Lp(a) plasma levels are known to be elevated in patients with: Nephrotic 
syndrome, end stage renal disease, Continuous Ambulatory Peritoneal Dialysis, 
hemodialysis, IDDM, hypothyroidism.135 
Several rare disorders such as LCAT, LPL deficiency, as well as liver disease 
and abetalipoproteinemia are associated with low plasma levels or lack of Lp(a).134 
 The sites and mechanism of Lp(a) removal from plasma are only poorly 
understood.134 There are conflicting observations regarding the catabolic pathways of 
Lp(a). Because of its resemblance to LDL, it was initially postulated that Lp(a) 
degradation was mediated by the LDL receptor (LDL-R) (50) via apoB-100 in the 
Lp(a). LDL-receptor seems to play only a minor role in Lp(a) elimination.123 Evidence 
is now accruing in favor of a nonspecific receptor pathway, both in human skin 
fibroblast cultures, human monocyte-derived macrophages, plasminogen receptor and 
the asialoglycoprotein receptor have been implicated. Recent observations suggest that 
the VLDL-receptor which is primarily expressed in skeletal muscle may be of 
significance for Lp(a) binding and degradation.123 In line with the fact that chronic 
renal failure is associated with increased Lp(a) plasma levels, it was suggested that the 
kidneys may be important for Lp(a) catabolism.123,136 Circulating Lp(a) interacts 
specifically with kidney  cells, or possibly other tissues, causing cleavage of 2/33/4 of 
the N-terminal part of apo(a) by a collagenase-type protease. Part of these apo(a) 
fragments are found as excretory products of Lp(a) in urine, but there are indications 
that they, in fact, represent the biologically active form of apo(a) and are possibly 
responsible for the atherogenicity of Lp(a).137 The fractional rates of catabolism for 
both apo B and apo(a) from Lp(a) were identical, and considerably lower than that 
observed for LDL, in line with the notion that the in vivo mechanisms of Lp(a) 
61 
 
clearance are different from the LDL receptor and eliminate the bulk of Lp(a) as an 
integral particle from the circulation.123,138 
GENETICS OF Lp(a) 
Lp(a) is a quantitative genetic trait. The distribution of Lp(a) in the population 
is highly skewed and very broad.139 The apo(a) gene is located in the long arm of  
chromosome 6 (6q26-27) where it is closely linked to the plasminogen gene.130,136 
 Sequencing of cloned human apo(a) complementary DNA revealed that apo(a) 
contains 10 different kringle IV subtypes, designed as types 1–10. The high 
quantitative polymorphism in the sequence encoding the plasminogen kingle IV type 2 
domain explains the high degree of individual allelic size polymorphism of the protein 
as, to date, more than 34 size alleles have been identified in the apo(a) locus, encoding 
as many detectable isoforms in plasma.130 Although the size of the apo(a) particle 
usually determines its rate of hepatic synthesis and secretion, there is profound 
interindividual variation in the Lp(a) levels for a given apo(a) size, suggesting that 
factors beyond gene size predict plasma levels. Interest is now focused on other apo(a) 
gene variations to explain this. Several polymorphisms in the apo(a) gene have been 
reported. Of these, a C/T variation in the promoter region of the apo(a) gene and a 
pentanucleotide repeat (TTTTAn) _1 kb upstream of the apo(a) gene have been studied 
in this regard.140 
FUNCTIONS OF Lp(a) 
The physiological functions of Lp(a) is unknown.141 
  Lp(a) promotes tissue repair 
It now seems that Lp(a) offers an evolutionary advantage to humans by 
promoting or accelerating the healing of wounds and the repair of tissue injuries and 
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vascular lesions. Lp(a) behaves as an acute-phase reactant. The sequence of the apo(a) 
gene contains several interleukin 6 (IL-6)-responsive elements that enhance 
transcription of the gene. IL-6 generates a marked, dose-dependent enhancement of 
apo(a) mRNA synthesis that leads to the accumulation of Lp(a) particles in hepatocyte 
culture, and several prospective clinical trials demonstrated significant rises in plasma 
Lp(a) after inducing different forms of acute phase response in vivo. Due to the 
additional presence of apo(a), Lp(a) can be recognized by a broad variety of receptors 
at the surface of endothelial cells, macrophages, fibroblasts, exposed sub-endothelial 
matrix, stabilized fibrin and platelets. Defensin, a peptide released from activated or 
senescent neutrophils, enhances the binding of Lp(a) to endothelial cells by 
approximately four-fold and to smooth muscle cells by six-fold.130 The large amount of 
apo(a) bound to the fibrin surface, the platelets and endothelial cells, inhibits the clot 
lysis mechanism. The growth factor like properties of Lp(a) also promotes vascular 
repair and cell regeneration.  
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                The role of Lp(a) in tissue repairing mechanism 
 
 Lp(a) inhibits fibrinolysis.130,141 
Lp(a) clearly inhibits plasminogen activation by t-PA in the presence of fibrin. 
Kinetic analysis of the data suggests that the inhibitory mechanism is uncompetitive. 
But there is no evidence to support the binding of Lp(a) directly to the enzyme-
substrate complex (t-PA and plasminogen). However, if we consider that the active 
catalytic complex is comprised of enzyme-substrate-activator (t-PA-plasminogen-
fibrin), and that Lp(a) binds to the activator, thereby making it unavailable for binding 
to the catalytic complex, we are left with the much less active enzyme-substrate 
complex (t-PAplasminogen).  
Another group of investigators have demonstrated that Lp(a) can inhibit the 
fibrinolytic activity of plasma generated by addition of streptokinase, but the 
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concentrations of Lp(a) required were significantly higher than noted in experiments 
with t-PA. It appears that streptokinase binds to Lp(a) and thereby inhibits 
streptokinase mediated plasminogen activation competitively as well as 
uncompetitively.142 The finding that Lp(a) also binds to glycoprotein IIb further 
supports the important role of Lp(a) in fibrinolysis.143 
 Lp(a) inhibits cancer growth and spread: 
OReilly et al explained that angiostatin, a 38 kDa fragment produced by cancer 
mediated proteolysis of plasminogen, inhibits the angiogenesis of tumours and 
metastasis (through plasminogen kringle domains I –IV) and inhibits endothelial cell 
migration (through plasminogen kringle domain V). Apo(a) portion of Lp(a) has high 
homologous to plasminogen residues. So, Lp(a) also decreasing the growth and spread 
of cancer like angiostatin. The concentration of Lp(a) is commonly reported to be 
elevated in cancer patients further supporting that Lp(a) has a biological role in the 
fight against cancer.130 
RELATIONSHIP BETWEEN Lp(a) AND METABOLIC 
SYNDROME 
Lp(a) AND ATHEROGENIC DYSLIPIDEMIA141 
Numerous epidemiological studies have shown that Lp(a) in plasma is a risk 
factor for a variety of cardiovascular diseases, including silent CAD, acute MI, 
asymptomatic carotid atherosclerosis,128,144  peripheral artery occlusive disease 
(PAOD), stroke and abdominal aortic aneurysm.145 The Framingham study reported 
that Lp(a) levels above 30mg/dl similar risk to TC > 240 mg /dl or HDL-C <35 mg/dl. 
 A few mechanisms have been proposed for the putative role of Lp(a) in IHD. 
Its incorporation into plaque and high affinity binding to glycosaminoglycans and 
65 
 
fibronectin suggest a direct atherogenic action in combination with elevated 
cholesterol. Lp(a) has less resistance to oxidation than does the LDL particle and can be 
actively taken up by scavenger receptors, leading to the formation of foam cells, 
smooth muscle cell proliferation, and plaque inflammation and instability. Further, 
Lp(a) may impair fibrinolytic activity by competing with plasminogen for fibrin 
binding, by competing with tissue-type plasminogen activator for fibrin binding or by 
direct binding to fibrin.143,144,146 
Lp(a) enters into and leaves the arterial wall by mechanisms similar to LDL and 
appears to accumulate more at sites of arterial injury than LDL. Its similarity to LDL 
may also contribute to the development of atherosclerosis. Lp(a) has also been shown 
to bind proinflammatory oxidized phospholipids recently associated with coronary 
artery disease. Oxidized Lp(a) is also implicated in the causation of endothelial 
dysfunction.144 Lp(a) has been shown to be critical in the initiation of atherogenesis 
through induction of chemotactic activity to circulating monocytes and enhancement of 
expression of intercellular adhesion molecule-1. An endothelial cell-activating effect of 
Lp(a) is potent surface expression of vascular cell adhesion molecule-1 (VCAM-1), 
intercellular adhesion molecule (ICAM)-1 and E-selectin. This may be a main event in 
the initiation process of atherogenic disease.147   
Lp(a) AND DIABETES 
In diabetes, conflicting reports are available regarding prognostic significance 
of Lp(a) levels. A few studies record that it may be elevated in insulin-dependent 
diabetes mellitus. Particularly, patients with microalbuminuria and proliferative 
retinopathy show higher Lp(a) levels. Similarly, Lp(a) has been correlated to CAD in 
diabetics in some studies, while other trials do not show any such correlation. South 
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Indian non-insulin-dependent diabetes mellitus (NIDDM) patients with high Lp(a) 
levels, however, show good correlation with CAD. 
Lp(a) AND PROTHROMBOTIC STATE 
Mechanisms by which Lp(a) may contribute to thrombus formation include 
inactivation of tissue factor pathway inhibitor, thus promoting coagulation, and 
attenuation of fibrinolysis through inhibition of plasminogen activation. It has been also 
shown that Lp(a) competes for the binding of plasminogen to the plasminogen receptor 
on endothelial cells and macrophages. All of these actions by Lp(a), occurring in vivo, 
create a prothrombotic state. Moreover, owing to its preferential uptake and 
degradation by macrophages, Lp(a) could colocalize with fibrin at intimal tissue sites 
resulting in a complex which is also atherogenic.127,128 
Apo(a) contains multiple tandem repeats of plasminogen-like kringle 4 (61% - 
75% homology) followed by a single copy of kringle 5 and of the protease domain(~ 
94% homology). Some of the plasminogen-like kringle 4 copies endow apo(a) with the 
ability to compete with plasminogen for binding to cells and fibrin. However, the 
substitution of the Arg-Val in plasminogen cleavage site by Ser-Ile in apo(a) impairs 
the generation of plasmin like activity by activators. Thus, the competitive binding of 
Lp(a) for lysine residues of fibrin and cell membrane proteins results in decreased 
plasmin formation and favour the deposition of fibrin and lipids within the vascular 
wall. Lp(a) was also shown to attenuate clot lysis in plasma and patients with elevated 
levels of Lp(a) were found to manifest significantly reduced endogenous clot lysis in 
plasma ex vivo.127 
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Lp(a) MEASUREMENT 
Immunometric analysis includes ELISA, DELPHIA, immunonephelometry, and 
turbidimetry. Commercially available assays include an immunoturbidimetric test, 
which can be run on automated chemistry analyzers.148 Most of these assays, except 
ELISA are based on the use of polyclonal antibodies from various animal species. An 
ELISA method in which, Lp(a) particles are captured using monoclonal antiLp(a) 
antibody , and a horseradish peroxidase enzyme conjugated polyclonal antiLp(a) 
antibody as the detection antibody has been described and is commercially available.126 
In another approach, both the capture and detection antibodies are specific for apo(a).  
 The structural heterogenicity of Lp(a) as a consequence of the apo(a) size 
heterogenicity has important implications for the accurate measurement of Lp(a). 
Antibodies are raised against either Lp(a) or apo(a) in the intact Lp(a) molecule since 
disassociation of apo(a) from apo B-100 decreases its immuno reactivity. If antibodies 
are raised against K-IV repeats, it would lead to heterogeneity due to variation in their 
numbers. A recent report suggests that patients suffering from coronary artery disease 
(CAD) excrete significantly higher amounts of apo(a) into the urine than controls and 
that urinary apo(a) is a valuable predictor of CAD. Using urinary apo(a) as a marker for 
CAD has the advantage of easier sampling compared to plasma samples.135 
 Owing to the lack of standardization, each laboratory must determine its own 
reference interval. This should be done with a suitably large population and should be 
done in consultation with cardiologists who will be using the results. The reference 
interval is method specific, and if changing methods, a new interval must be 
established.148 
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 It is not known whether risk is associated simply with an elevated number of 
Lp(a) particles in the circulation as measured using an anti apo-B antibody or else 
related to the presence apo(a) size polyforms. It is likely that both factors influence 
risk. Lp(a) concentrations can also be expressed in terms of particle number, the mass 
of apo (a), apoB 100 or Lp(a) cholesterol. Which approach will best predict the risk of 
CHD is yet to be determined. At present Lp(a) values are expressed in terms of total 
Lp(a) mass. Currently a value of about 30 mg/dl of total Lp(a) particle mass is used as a 
cut off 148, above which elevated levels of Lp(a) are associated with increased risk of 
CHD. An International Federation of Clinical Chemistry (IFCC) committee has been 
set to work towards standardizing Lp(a). Apo(a) protein, mRNA and DNA size 
polymorphism studies demonstrate that the number of K-IV repeats in the gene and the 
resulting size of the protein are inversely correlated with Lp(a) levels in the plasma in 
all populations studied so far.139,145 Because there is profound inter individual variation 
of Lp(a) levels for a given apo(a) size, suggesting that factors beyond gene size predict 
plasma levels, interest has focused on other apo(a) gene variations. Several apo(a) gene 
polymorphisms have been reported. A pentanucleotide sequence repeat polymorphism 
(TTTTA) at position-1373 before the translation initiation codon of the apo(a) gene and 
a C/T variation in the promoter region of apo(a) gene may be some of the factors 
associated with variable plasma Lp(a) concentration. The TTTTA polymorphism could 
account for about 10–14% of the inter-individual variations of Lp(a) levels in 
Caucasians.135,139 
! Increased levels of Lp(a)  are observed in blacks. Despite the higher levels of 
Lp(a) in blacks, they appear to have a lower death rate from coronary heart disease than 
white men.125,135 
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OTHER FACTORS AFFECTING PLASMA LEVELS OF Lp(a) 
Lp(a) levels, do not alter with the age. Sex, anthropometric parameters, 
environmental factors, other coronary risk factors and other lipoproteins are not 
significantly altering the Lp(a) levels135,145 but alcohol consumption, hypothyroidism 
and  hormones (growth hormone, estrogens) affects the Lp(a) levels. Several renal 
diseases, familial hypercholesterolemia, rheumatoid arthritis and drugs such as 
cyclosporin, danazol, and stanazolol increases the Lp(a) levels. 
Lp(a) levels are not readily amenable by dietary restriction also. Moderate 
drinking of alcohol lowers plasma Niacin and hormone replacement therapy decreases 
the Lp(a) levels.. The high heritability of plasma Lp(a) concentrations and their lack of 
responsiveness to environmental influences suggest a potential value of Lp(a) as a 
stable risk factor for vascular disease. 
 
  
 
 
 
 
MATERIALS &  METHODS 
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MATERIALS AND METHODS 
SOURCES OF DATA 
 Patients and bystanders who attended the medicine OPD of Sree Mookambika 
Institute of Medical Sciences, Kulasekharam, Tamilnadu for routine medical check up 
formed the subjects for the present cross-sectional study. The total of 136 subjects that 
came to the hospital during January 2014 to April 2014 was enrolled into the study.  
DIAGNOSTIC CRITERIA 
Metabolic syndrome was diagnosed according to the NCEP-ATP III criteria 
(Third Report of the National Cholesterol Education Program Expert Panel on 
Detection, Evaluation and Treatment of High Blood Cholesterol in Adults – Adult 
Treatment Panel III) and IDF criteria. 
 INCLUSION CRITERIA 
1. Patients and bystanders attending medicine OPD of Sree Mookambika Institute 
of Medical Sciences. 
2. Age between 24-39 years. 
EXCLUSION CRITERIA 
1. Subjects having following conditions to be excluded. 
Pregnancy, Congenital diseases, Severely ill patients.  
2. Those who are not willing to participate. 
 METHOD OF COLLECTION OF DATA  
 Informed consent was taken from the all subjects. A pre-structured and 
pretested proforma was used to collect the data. Baseline data including age, gender, 
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religion, detailed medical history, clinical examinations and relevant investigations 
were included as part of the methodology. 
The following parameters were collected: age, gender, religion, waist 
circumference, blood pressure and fasting clinical chemistry parameters. Waist 
circumference was measured using a non-stretchable fibre measuring tape. The subjects 
were asked to stand erect in a relaxed position with both feet together on a flat surface. 
Waist circumference was taken at the midpoint between the lower margin of the last 
palpable rib and the top of the iliac crest. Blood pressure was recorded in the sitting 
position in the right arm to the nearest 2 mmHg using the mercury sphygmomanometer 
(Diamond Deluxe BP apparatus, Pune, India). Two readings were taken 5 min apart 
and the mean of the two was taken as blood pressure. Blood samples were collected 
from each participant after a 9-hour overnight fasting and employing standard infection 
prevention procedures. The collected blood samples were used to determine the 
concentrations of HDL-cholesterol, triglyceride, lipoprotein (a) and fasting glucose. 
 
1. ESTIMATION OF LIPOPROTEIN (a) BY LATEX TURBIDIMETRY 
CLINICAL SIGNIFICANCE  
Lp(a) is a low density lipoprotein-like particle containing apolipoprotein B-100 
disulphide-linked to one large glycoprotein called apolipoprotein (a). Many 
investigators have confirmed that a high Lp(a) concentration represents an indicator of 
risk for cardiovascular disease, especially when serum LDL-cholesterol or Apo B are 
elevated. The quantification of Lp(a) in serum or plasma is important for identification 
of individuals at risk for developing atherosclerosis.  
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 PRINCIPLE OF THE METHOD  
The Lp(a)-turbilatex is a quantitative turbidimetric test for the measurement of 
Lp(a) in human serum or plasma.  
Latex particles coated with antibodies anti-Lp(a) are agglutinated when mixed 
with samples containing Lp(a). The agglutination causes an absorbance change, 
dependent upon the Lp(a) contents of sample that can be quantified by comparison 
from a calibrator of known Lp(a) concentration.  
REAGENTS 
Diluent (R1) Glycine buffer50 mmol/L, pH 9.0. Sodium azide 0.95 g/L 
Latex (R2) Latex particles coated with mouse monoclonal anti-human 
Lp(a), pH 8.2. Sodium azide 0.95 g/L. 
Optional Ref.:1107022 Lp(a) calibrator 
Ref.:1107024 Lp(a) Control 
 
PROCEDURE  
1. Bring the working reagent and the photometer (cuvette holder) to 37ºC.  
2. Assay conditions:  
Wavelength: 570 nm (540-600)  
Temperature: 37ºC  
Cuvette ligth path: 1 cm  
            3. Adjust the instrument to zero with distilled water. 
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 4. Pipette into a cuvette   
 R1: Diluent (μl)  400  
 R2: Latex (μl)  100  
Calibrator or sample (μl)  7  
  
           5. Mix and read the absorbance immediately (A1) and after 4 minutes (A2) of 
the sample addition. 
 
 REFERENCE VALUES  
Normal values up to 30 mg/dl. 
2. ESTIMATION OF BLOOD GLUCOSE  
¾ Gesan Mono reagent LR (Liquid Reagent) 6 x 50 ml kit used. 
¾ Colorimetric enzymatic method GOD-POD. 
PRINCIPLE 
 Glucose + O2 + H2O         
GOD            H 2O2 + Gluconic acid 
2H2O2 + phenol + 4 aminophenazone                   
POD  
 Quinonimine       (coloured     
compound) +4H2O2. 
Glucose is oxidized, in presence of glucose oxidase (GOD), into gluconic acid 
and hydrogen peroxide. This one reacts, by peroxidase (POD), with 4 aminophenazone 
and phenol giving a coloured compound whose colour intensity is directly proportional 
to the glucose concentration in the tested sample.  
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REAGENTS  
 R1        Phosphate buffer    pH  7.4    100.0 mmol/l 
   Phenol                                       9.0  mmol/l 
              GOD ≥                                    25000 U/l 
   POD  ≥                                     1500  U/l    
 4 aminophenazone                    2.3 mmol/l        
SAMPLE 
• Serum heparinised plasma or EDTA plasma used. 
• Diluted urine 1:10 
•  Do not use samples with hemolysis  
• Specimens should be separated from cells as soon as possible after collection to 
avoid loss due to glycolysis 
• The glucose is stable in the samples upto 3 days at 2-8o C, after the addition of a 
glycolytic inhibitor as sodium fluoride, potassium fluoride.. 
PROCEDURE 
Wavelength  510 (500-550 ) nm 
Working temperature 37oC 
Optical path 1 cm 
Reaction “End point”  
Bring the reagents at 15-25oC before use them. 
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MONOREAGENT PROCEDURE “SAMPLE STARTER” 
 Blank Standard Sample 
Working reagent 1000 µl 1000µl 1000µl 
Distilled water 10µl _ _ 
Sample _ _ 10µl 
Standard _ 10µl _ 
 
 Mix, then incubate 10 minutes at 37oC. Measure the absorbance of sample (EC) 
and standard (ESTD) against the reagent blank. 
CALCULATION 
 Glucose (mg/dl)  ͦ (mmol/l) =EC/ESTD x concentration of standard 
Conversion factor 
  Glucose (mg/dl) x 0.05551 = glucose (mmol/l) 
REFERENCE VALUES 
 Serum-plasma 70-105 mg/dl (3.9-5.8 mmol/l) 
     Urine           <0.5g /24h     (<28 mmol/24h) 
REAGENTS PREPARATIONS 
 Reagent is liquid and ready to use. 
Storage and Stability: 
• Store the kit at 2-8ºC. Do not freeze the reagents. 
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• After opening, the reagent is stable 90 days if recapped immediately and 
protected from contamination, evaporation, direct light and stored at the 
correct temperature. 
   Precaution: 
      Reagents contain sodium azide (0.095%) as preservative. Avoid swallowing and     
contacting with skin, eyes and mucous membranes. 
3. ESTIMATION OF SERUM TRIGLYCERIDES  
¾ Gesan triglycerides monoreagent LR Liquid (6x50 ml) Reagent Kit for 
measurement of triglycerides in serum or plasma. 
¾ Colorimetric enzymatic method Glycerol phosphate oxidase - peroxidase 
method.. 
PRINCIPLE  
Glycerol released from hydrolysis of triglycerides by lipoprotein lipase is 
converted by glycerol kinase into glycerol-3-phosphate, which is oxidized by glycerol 
phosphate oxidase to dihydroxyacetone phosphate and hydrogen peroxide. In the 
presence of peroxidase, hydrogen peroxide oxidizes phenolic chromogen to a red 
coloured compound/ 
   Triglycerides + H2O           
Lipoprotein lipase               Glycerol + Fatty acid 
  Glycerol + ATP             Glycerol kinase  Glycerol 3 phosphate + ADP 
 Glycerol 3 phosphate + O 2  
Glycerol 3 phosphate oxidase  Dihydroxy acetone phosphate + H2O2 
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   H2O2 + 4 Aminophenazone +p-chlorophenol    
Peroxidase Red colour Quinoneimine 
 Intensity of coloured compound is proportional to the concentration of 
triglycerides in the sample. 
REAGENTS 
R1              
 PIPES buffer 100.0 mmol/l  
 Phenol  16.0 mmol/l 
Lipoprotein lipase ≥4000 U/l 
Glycerol kinase ≥2000 U/l 
Peroxidase ≥2500 U/l 
ATP 0.8 mmol/l 
4 Aminophenazone 1.4 mmol/l 
Glycerol 3 phosphate oxidase ≥2000 U/l 
  
REAGENTS PREPARATION 
 Reagent is liquid and ready to use. Keep out the reagents from refrigerator only 
for the use and recap them immediately. 
STORAGE 
• Store the kit at 2-8oC. 
• After opening, the vials R1 is stable 90 days if recapped immediately & 
protected from evaporation, direct light and contamination and stored at 
the correct temperature. 
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SPECIMEN COLLECTION AND PREPARATION 
¾ Serum-heparinized plasma or EDTA plasma 
¾ In the samples, stored at 2-8oC and at -20oC, the triglycerides are stable, 
respectively, upto 3 days and 12 months. 
¾ It’s advisable, in presence of strongly lipemic, jaundiced or turbid 
serum, to prepare a blank of the sample using saline solution. 
PROCEDURE 
Wavelength  510 (500-550 ) nm 
Working temperature 37oC 
Optical path 1 cm 
Reaction “End point” (increasing)  
      Bring the reagents at 15-25oC before use. 
MONO REAGENT PROCEDURE “SAMPLE STARTER” 
 Blank Standard Sample 
Working reagent 1000 µl 1000 µl 1000 µl 
Distilled water  10 µl _ _ 
Sample _ _ 10 µl 
Standard _ 10 µl _ 
 Mix, then incubate for 5 minutes at 37oC. Measure the absorbance of sample 
(EC) and standard (ESTD) against the reagent blank.   
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CALCULATION 
 Triglycerides (mg/dl) or (mmol/l) = EC/ESTD X Concentration of standard 
Conversion factor 
 Triglycerides (mg/dl) x 0.01126 = Triglycerides (mmol/l) 
REFERENCE VALUES (to 37oC) 
 Serum – Plasma 
Men 60-165 mg/dl (0.68-1.86 mmol/l) 
Women 40-140 mg/dl (0.45-1.58 mmol/l) 
    
 It has been noticed that the values obtained using the plasma as sample are, 
from 2% to 4% lower than values obtained using the serum. 
4. ESTIMATION OF SERUM HDL-CHOLESTEROL  
¾ Bio systems kit 
¾ Direct detergent method 
PRINCIPLE 
 The chlolesterol from LDL, VLDL and chylomicrons is broken down by the 
cholesterol oxidase in an enzymatic accelerated non-colour forming reaction. The 
detergent present in the reagent B, solubilizes cholesterol from HDL in the sample. The 
HDL cholesterol is then spectrophotometrically measured by means of the coupled 
reactions described below. 
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Cholesterol esters + H2O    
Cholesterol esterase Cholesterol + Fatty acid 
Cholesterol + ½ O2 + H2O         
Cholesterol oxidase      Cholestenone + H2O2 
2 H2O2 + 4 amino antipyrine + DSBmT    
Peroxidase  Quinoneimine (Red colour) + 4 H2O 
REAGENT CONTENTS AND COMPOSITION 
A. Reagent 1 x 60 ml. Good’s buffer, cholesterol oxidase < 1 U/ml, peroxidise < 1 
U/ml, N,N-bis (4 sulfobutyl)-m-toluidine (DSBmT) 1 mmol/l, accelerator 
1mmol/l. 
B. Reagent 1 x 20 ml. Good’s buffer, cholesterol esterase <1.5 U/ml, 4 amino 
antipyrine 1 mmol/l, ascorbate oxidase < 3.0 KU/l, detergent. 
STORAGE 
 Store at 2 – 8oC. 
 Indications for deterioration: Presence of particulate material, Turbidity. 
AUXILIARY REAGENTS 
 Serum HDL/LDL calibrator (Biosystems code.11693) 
 Human serum. Concentration is given on the label. The concentration value is 
traceable to the CDC Reference Measurement Procedure (Centers for disease control 
and prevention). Reconstitute with 1.0 ml of distilled water. Stable for 1 week at 2-8oC 
or for 2 months at -18oC when frozen in aliquots.  
REAGENT PREPARATION 
 Reagents are provided ready to use. 
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SAMPLES 
 Serum collected by standard procedures. HDL cholesterol in serum or plasma is 
stable for 7 days at 2-8oC. EDTA, lithium or sodium, heparin may be used as 
anticoagulants. 
PROCEDURE 
1. Bring the reagents and the photometer to 37oC. 
2. Pipette into a cuvette 
Reagent A 
Serum /calibrator                                  
750 µl 
7   µl 
3. Mix and insert the cuvette into the photometer. Start the stopwatch. After 5 
minutes, read the absorbance (A1) at 600/700 nm against distilled water. 
4. Pipette into a cuvette 
 
                     Mix.   
5. After 5 minutes, read the absorbance (A2) at 600/700 nm. 
CALCULATIONS 
 The cholesterol HDL concentration is calculated using the following general 
formula. 
 C sample = (A2 – A1) sample/ (A2 – A1) calibrator X C calibrator 
 
 
Reagent B 250 µl 
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REFERENCE VALUES 
 HDL cholesterol concentrations vary considerably with age and sex. The 
following cut-off point has been recommended for identifying individuals at high risk 
of coronary artery disease. 
Up to 35 mg/dl = 0.91 mmol/l 
 >60       mg/dl = >1.56 
mmol/l 
High risk 
Low risk 
 
STATISTICAL ANALYSIS 
 Data collected were entered in excel. Analysis was done by SPSS version 
18.Simple proportion, Percentage, Mean, Standard deviation, and Pearson correlation 
co-efficient were calculated. Appropriate test of significance like chi-square test and “t” 
test were done. Values of p < 0.05 were considered statistically significant. 
 
  
 
 
 
 
                           RESULTS 
 
83 
 
5. RESULTS 
5.1 GENERAL CHARACTERISTICS OF THE STUDY POPULATION 
5.1.1 Age Distribution  
Age Number Percentage 
24 - 29 Years 43 31.6 
 30 - 34 Years 28 20.6 
 35 - 39 Years 65 47.8 
Total 136 100 
 
Descriptive Statistics 
 Number Minimum Maximum Mean Std. Deviation
AGE 136 24 39 32.60 5.04 
 
 There were 136 persons taken for this study. Out of them, maximum number of 
persons 65 (47.8%) comes under the category of 35-39 years, followed by 43 (31.6%) 
persons comes under the category of 24-29 years, and then 28 (20.6%) persons comes 
under the category of 30-34 years. The youngest age of the person participated in this 
study is 24 years and the oldest is 39 years with the mean age of 32.6 years. 
 
5.1.2 Sex Distribution  
Sex Number Percentage 
Male 78 57.4 
Female 58 42.6 
Total 136 100 
 
 Out of 136 persons participated in this study, maximum number of persons 78 
(57.4%) are males, followed by females 58 (42.6%). 
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5.1.3 Religion 
Religion Number Percentage 
Hindu 82 60.3 
Christian 42 30.9 
Muslim 12 8.8 
Total 136 100 
 
 According to religion wise, 82 (60.3%) persons coming under Hindu, followed 
by 42 (30.9%) persons of Christians, and 12 (8.8%) persons of Muslims.  
 
5.2 PARAMETERS OF METABOLIC SYNDROME INCLUDING Lp(a) 
 
5.2.1 DESCRIPTION OF PARAMETERS 
Descriptive Statistics 
 Number Minimum Maximum Mean Std. Deviation 
WC 136 78 104 91.92 5.46 
SBP 136 100 160 131.56 11.77 
DBP 136 70 100 84.07 7.11 
FBS 136 82 170 106.82 13.32 
TGL 136 112 204 155.71 22.18 
HDL 136 25 54 40.50 6.88 
Lp(a) 136 13.12 90.91 43.36 21.77 
 
 According to the parameters of metabolic syndrome, minimum waist 
circumference is 78 cm and maximum is 104 cm with the mean and standard deviation 
of 91.92 ± 5.46. Minimum systolic BP is 100 mmHg and maximum is 160 mmHg with 
the mean and standard deviation of 131.56 ± 11.77, followed by diastolic BP, minimum 
is 70 mmHg and maximum is 100 mmHg with the mean and standard deviation of 
84.07 ± 7.11.About fasting blood sugar, minimum is 82 mg/dl and maximum is 170 
mg/dl with the mean and standard deviation of 106.82 ± 13.32. In lipids, minimum 
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triglyceride is 112 mg/dl and maximum is 204 mg/dl with the mean and standard 
deviation of 155.71 ± 22.18, followed by High density lipoprotein cholesterol, 
minimum is 25 and maximum is 54 with the mean and standard deviation of 40.50 ± 
6.88. According to the lipoprotein (a) values, minimum is 13.12 and maximum is 90.91 
with the mean and standard deviation of 43.36 ± 21.77. 
 
5.2.2 PREVALENCE OF ABNORMAL PARAMETERS 
 Number Percentage 
Obesity  103 75.7 
History of Anti- HTN Treatment 32 23.5 
Abnormal SBP 51 37.5 
Abnormal DBP 52 38.2 
Hypertensive 61 44.9 
History of Anti- DM Treatment 38 27.9 
Abnormal FBS 47 34.6 
Diabetic 50 36.8 
History of Anti- lipid Treatment 21 15.4 
High TGL 62 45.6 
Abnormal TGL 64 47.1 
Low  HDL 41 30.1 
Abnormal HDL 50 36.8 
Increased Lp(a) 90 66.2 
  
 In our study population, maximum number of persons 103 (75.7%) have 
affected by obesity (Increased waist circumference) followed by 64 (47.1%) have 
abnormal triglyceride levels. Among the abnormal triglyceride levels, 62 (45.6%) have 
high triglyceride levels and 21 (15.4%) have history of lipid lowering drug treatment. 
Next maximum 61 (44.9%) persons affected by hypertension and then 50 (36.8%) 
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affected by diabetes and abnormal high density lipoprotein cholesterol levels. Among 
hypertensive patients 52 (38.2%) having abnormal diastolic blood pressure and 51 
(37.5%) have abnormal systolic blood pressure levels. Among diabetic patients 47 
(34.6%) having abnormal fasting blood sugar levels and 38 (27.9%) have history of anti 
diabetic treatment. Among abnormal high density lipoprotein cholesterol 41 (30.1%) 
having low high density cholesterol levels and 21 (15.4%) have history of lipid 
lowering drug treatment. Finally in total number of 136 persons, 90 (66.2%) persons 
have increased lipoprotein (a) levels. 
 
5.3 PREVALENCE OF INDIVIDUAL METABOLIC SYNDROME 
PARAMETERS AMONG AGE AND SEX CATEGORIES  
 
5.3.1 OBESITY 
5.3.1.1 Obesity and Age 
 
Age Category 
OBESE 
Total 
Yes No 
24 - 29 Years 21 (48.8%) 22 (51.2%) 43 (100%) 
30 - 34 Years 21 (75.0%) 7 (25.0%) 28 (100%) 
35 - 39 Years 61 (93.8%) 4 (6.2%) 65 (100%) 
Total 103 (75.7%) 33 (24.3%) 136 (100%) 
Chi2 Value – 28.539   df – 2   p-Value – 0.000 (Significant) 
 
 In our study, maximum number of persons 61 (93.8%) have affected by obesity 
comes under the age group of 35-39 years, followed by 21(75%) persons of 30-34 years 
and 21 (48.8%) persons of 24-29 years. So, prevalence of obesity with the age category 
has significant correlation according to the p-value 0.000 (<0.01). 
 
 
 
 
87 
 
5.3.1.2 Obesity and Sex 
Sex Category 
OBESE 
Total 
Yes No 
Male 52 (66.7%) 26 (33.3%) 78 (100%) 
Female 51 (87.9%) 7 (12.1%) 58 (100%) 
Total 103 (75.7%) 33 (24.3%) 136 (100%) 
Chi2 Value – 8.185   df – 1   p-Value – 0.004 (Significant) 
  
 According to the sex category, maximum percentage of females 51 (87.9%) 
have affected by obesity than males 52 (66.7%).prevalence of obesity with the sex 
category also have significant correlation according to the p-value 0.004 (<0.01).  
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5.3.2 HYPERTENSION 
5.3.2.1 Hypertension and Age 
 
Age Category 
HYPERTENSION 
Total 
Yes No 
24 - 29 Years 0 (0.0%) 43 (100%) 43 (100%) 
30 - 34 Years 11 (39.3%) 17 (60.7%) 28 (100%) 
35 - 39 Years 50 (76.9%) 15 (23.1%) 65 (100%) 
Total 61 (44.9%) 75 (55.1%) 136 (100%) 
Chi2 Value – 62.351   df – 2   p-Value – 0.000 (Significant) 
 In our study, maximum number of persons 50 (76.9%) affected by 
hypertension, comes under the age group of 35-39 years, followed by 11 (39.3%) 
persons in the age group of 30-34 years. Nobody affected by hypertension, in the age 
group of 24-29 years. Prevalence of hypertension with the age category has significant 
correlation according to the p-value 0.000 (<0.01). 
5.3.2.2 Hypertension and Sex 
Sex Category 
HYPERTENSION 
Total 
Yes No 
Male 41 (52.6%) 37 (47.4%) 78 (100%) 
Female 20 (34.5%) 38 (65.5%) 58 (100%) 
Total 61 (44.9%) 75 (55.1%) 136 (100%) 
Chi2 Value – 4.397   df – 1   p-Value – 0.036 (Significant) 
 According to hypertension and sex category, maximum number of males 41 
(52.6%) were affected by hypertension than the females 20(34.5%). Prevalence of 
hypertension with the age category has significant correlation according to the p-value 
0.036 (<0.05).  
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5.3.3 DIABETS MELLITUS 
5.3.3.1 Diabetes Mellitus and Age 
 
Age Category 
DIABETES MELLITUS 
Total 
Yes No 
24 - 29 Years 9(20.9%) 34(79.1%) 43 (100%) 
30 - 34 Years 11(39.2%) 17(60.8%) 28 (100%) 
35 - 39 Years 30(46.2%) 35(53.8%) 65 (100%) 
Total 50(36.7%) 86(63.3%) 136 (100%) 
Chi2 Value – 13.347   df – 2   p-Value – 0.001 (Significant) 
 
 In our study, maximum number of persons 30 (46.2%) have affected by 
diabetes mellitus comes under the age group of 35-39 years, followed by 11 (39.2%) 
persons of 30-34 years and 9 (20.9%) persons of 24-29 years. So, prevalence of 
diabetes mellitus with the age category has significant correlation according to the p-
value 0.000 (<0.01). 
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5.3.3.2 Diabetes Mellitus and Sex 
Sex Category 
DIABETES MELLITUS 
Total 
Yes No 
Male 32(41.0%) 46(59.0%) 78 (100%) 
Female 18(31.0%) 40(69.0%) 58 (100%) 
Total 50(36.8%) 86(63.2%) 136 (100%) 
Chi2 Value –1.428  df – 1   p-Value – 0.232 (Significant) 
 
 According to diabetes mellitus and sex category, maximum number of males 32 
(41.0%) were affected by diabetes mellitus than the females 18(31.0%).Prevalence of 
diabetes mellitus with the age category has significant correlation according to the p-
value 0.232 (<0.05).  
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5.3.4 ABNORMAL TGL 
5.3.4.1 Abnormal TGL and Age 
 
Age Category 
ABNORMAL TGL 
Total 
Yes No 
24 - 29 Years 1 (2.3%) 42(97.7%) 43 (100%) 
30 - 34 Years 19(67.9%) 9(32.1%) 28 (100%) 
35 - 39 Years 44(67.7%) 21(32.3%) 65 (100%) 
Total 64(47.1%) 72(52.9%) 136 (100%) 
Chi2 Value – 50.507   df – 2   p-Value – 0.000 (Significant) 
 
 In our study, maximum number of persons 44 (67.7%) have affected by 
abnormal triglycerides comes under the age group of 35-39 years, followed by 19 
(67.9%) persons of 30-34 years and 1 (2.3%) persons of 24-29 years. So, prevalence of 
abnormal triglycerides with the age category has significant correlation according to the 
p-value 0.000 (<0.01). 
 
5.3.4.2 Abnormal TGL and Sex 
Sex Category 
ABNORMAL TGL 
Total 
Yes No 
Male 42(53.8%) 36(46.2%) 78 (100%) 
Female 22(37.9%) 36(62.1%) 58 (100%) 
Total 64(47.1%) 72(52.9%) 136 (100%) 
Chi2 Value –3.382  df – 1   p-Value – 0.066 (Not Significant) 
 
 According to abnormal triglycerides and sex category, maximum number of 
males 42 (53.8%) were affected by abnormal triglycerides levels than the females 22 
(37.9%). Prevalence of abnormal triglycerides with the age category has no significant 
correlation according to the p-value 0.066 (>0.05). 
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5.3.5 ABNORMAL HDL 
5.3.5.1 Abnormal HDL and Age 
 
Age Category 
ABNORMAL HDL 
Total 
Yes No 
24 - 29 Years 2(4.7%) 41(95.3%) 43 (100%) 
30 - 34 Years 9(32.1%) 19(67.9%) 28 (100%) 
35 - 39 Years 39(60%) 26(40.0%) 65 (100%) 
Total 50(36.8%) 86(63.2%) 136 (100%) 
Chi2 Value – 34.426   df – 2   p-Value – 0.000 (Significant) 
 In our study, maximum number of persons 39 (60%) have affected by abnormal 
HDL levels comes under the age group of 35-39 years, followed by 9 (32.1%) persons 
of 30-34 years and 2 (4.7%) persons of 24-29 years. So, prevalence of abnormal HDL 
levels with the age category has significant correlation according to the p-value 0.000 
(<0.01). 
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5.3.5.2 Abnormal HDL and Sex 
Sex Category 
ABNORMAL HDL 
Total 
Yes No 
Male 25(32.1%) 53(67.9%) 78 (100%) 
Female 25(43.1%) 33(56.9%) 58 (100%) 
Total 50(36.8%) 86(63.2%) 136 (100%) 
Chi2 Value – 1.748   df – 1   p-Value – 0.186 (Significant) 
 
 According to abnormal HDL levels and sex category, maximum number of 
males 25 (32.1%) were affected by abnormal HDL levels than the females 25 (43.1%). 
Prevalence of abnormal HDL levels with the age category has significant correlation 
according to the p-value 0.186 (<0.05). 
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5.4 PREVALENCE OF METABOLIC SYNDROME 
 
MS CRITERIA Category  Number Percentage 
Modified NECP 
ATP III 
Yes 64 47.1 
No 72 52.9 
IDF 
YES 61 44.9 
No 75 55.1 
 
 In our study population, prevalence of metabolic syndrome is 47.1% (64 
persons) according to the Modified NCEP ATP III Criteria and according to the IDF 
Criteria; prevalence is 44.9% (61 persons). It is little lower than the NCEP ATP III 
Criteria prevalence. 
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5.4.1 METABOLIC SYNDROME AMONG AGE CATEGORY  
5.4.1.1 Metabolic Syndrome by Modified NECP ATP III and Age  
 
Age Category 
MS BY MODIFIED NECP ATP III 
Total 
Yes No 
24 - 29 Years 0 (0%) 43(100%) 43 (100%) 
30 - 34 Years 14(50%) 14(50%) 28 (100%) 
35 - 39 Years 50(76.9%) 15(23.1%) 65 (100%) 
Total 64(47.1%) 72(52.9%) 136 (100%) 
Chi2 Value – 61.589   df – 2   p-Value – 0.000 (Significant) 
 
 According to the Modified NCEP ATP III Criteria, prevalence of metabolic 
syndrome is maximum 50 (76.9%) persons at the age group of 35-39 years, followed 
by 14 (50%) persons in the age group of 30-34 years and no persons in the age group of 
24-29 years in our study population. Prevalence of metabolic syndrome (By Modified 
NCEP ATP III Criteria) with the age category has significant correlation according to 
the p-value 0.000 (<0.01). 
 
5.4.1.2 Metabolic Syndrome by IDF and Age 
 
Age Category 
MS BY IDF 
Total 
Yes No 
24 - 29 Years 0(0%) 43 (100.0%) 43 (100%) 
30 - 34 Years 13(46.4%) 15(53.6%) 28 (100%) 
35 - 39 Years 48(73.8%) 17(26.2%) 65 (100%) 
Total 61(44.9%) 75(55.1%) 136 (100%) 
Chi2 Value – 57.091   df – 2   p-Value – 0.000 (Significant) 
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 According to the IDF Criteria, prevalence of metabolic syndrome is maximum 
48 (73.8%) persons at the age group of 35-39 years, followed by 13 (46.4%) persons in 
the age group of 30-34 years and no persons in the age group of 24-29 years in our 
study population. Prevalence of metabolic syndrome (By IDF Criteria) with the age 
category has significant correlation according to the p-value 0.000 (<0.01). 
5.4.2 METABOLIC SYNDROME AMONG SEX CATEGORY  
5.4.2.1 Metabolic Syndrome by Modified NECP ATP III and Sex 
Sex Category 
MS BY MODIFIED NECP ATP III 
Total 
Yes No 
Male 37(47.4%) 41(52.6%) 78 (100%) 
Female 27(46.6%) 31(53.4%) 58 (100%) 
Total 64(47.1%) 72(52.9%) 136 (100%) 
Chi2 Value – 0.10   df – 1   p-Value – 0.919 (Not Significant) 
 According to Modified NCEP ATP III Criteria, maximum numbers of males 37 
(47.4%) were affected by metabolic syndrome than the females 27 (46.6%). Prevalence 
of metabolic syndrome with the sex category has no significant correlation according to 
the p-value 0.919 (>0.05).  
 
5.4.2.2 Metabolic Syndrome by IDF and Sex 
Sex Category 
MS BY IDF 
Total 
Yes No 
Male 36(46.2%) 42(53.8%) 78 (100%) 
Female 25(43.1%) 33(56.9%) 58 (100%) 
Total 61(44.9%) 75(55.1%) 136 (100%) 
Chi2 Value – 0.125   df – 1   p-Value – 0.724 (Not Significant) 
 According to IDF Criteria, maximum numbers of males 36 (46.2%) were 
affected by metabolic syndrome than the females 25 (43.1%). Prevalence of metabolic 
syndrome with the sex category has no significant correlation according to the p-value 
0.724 (>0.05).  
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5.4.3 METABOLIC SYNDROME AMONG RELIGION CATEGORY  
5.4.3.1 Metabolic Syndrome by Modified NECP ATP III and Religion 
Religion Category 
MS BY MODIFIED NECP ATP III 
Total 
Yes No 
Hindu 39(47.6%) 43(52.4%) 82 (100%) 
Christian 19(45.2%) 23(54.8%) 42 (100%) 
Muslim  6(50%) 6(50%) 12 (100%) 
Total 64(47.1%) 72(52.9%) 136 (100%) 
Chi2 Value – 0.106   df – 2   p-Value – 0.948 (Not Significant) 
 According to the Modified NCEP ATP III Criteria, religion wise, maximum 
50% (6 persons) prevalence of metabolic syndrome is seen in Muslims, followed by 
Hindus 47.6% (39 persons) and then Christians 45.2% (19 persons). Prevalence of 
metabolic syndrome (By Modified NCEP ATP III Criteria) with the religion category 
has no significant correlation according to the p-value 0.948 (>0.05). 
 
5.4.3.2 Metabolic Syndrome by IDF and Religion 
Religion Category 
MS BY IDF 
Total 
Yes No 
Hindu 38(46.3%) 44(53.7%) 82 (100%) 
Christian 17(40.5%) 25(59.5%) 42 (100%) 
Muslim  6(50%) 6(50%) 12 (100%) 
Total 61(44.9%) 75(55.1%) 136 (100%) 
Chi2 Value – 0.527  df – 2   p-Value – 0.768 (Not Significant) 
 According to the IDF Criteria, religion wise, maximum 50% (6 persons) 
prevalence of metabolic syndrome is seen in Muslims, followed by Christians 40.5% 
(17 persons) and then Hindus 46.3% (38 persons). Prevalence of metabolic syndrome 
(By IDF Criteria) with the religion category has no significant correlation according to 
the p-value 0.768 (>0.05). 
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5.5. DISTRIBUTION OF METABOLIC SYNDROME PARAMETERS  
5.5.1 Distribution of Metabolic Syndrome Parameters among Age Category 
AGE.CAT WC SBP DBP FBS TGL HDL 
24 - 29 Years 
N 43 43 43 43 43 43
Mean 88.00 119.67 77.81 96.33 133.44 44.51
SD 4.018 7.596 4.447 6.951 10.664 4.930
 30 - 34 Years 
N 28 28 28 28 28 28
Mean 91.57 132.14 84.86 106.36 163.89 40.57
SD 5.666 7.075 7.271 8.274 17.635 5.909
35 - 39 Years 
N 65 65 65 65 65 65
Mean 94.66 139.17 87.88 113.97 166.92 37.82
SD 4.560 8.916 5.476 13.691 18.487 7.137
Total 
N 136 136 136 136 136 136
Mean 91.92 131.56 84.07 106.82 155.71 40.50
SD 5.462 11.772 7.107 13.316 22.180 6.877
F - Value 26.659 73.895 42.067 33.782 59.525 14.776
p- Value 0.000* 0.000* 0.000* 0.000* 0.000* 0.000*
* Significant at 0.01 level 
 Table 5.5.1 shows the distribution of individual metabolic syndrome parameters 
among the various age categories with their mean and standard deviation. All the 
metabolic syndrome parameters waist circumference, systolic blood pressure, diastolic 
blood pressure, fasting blood sugar, abnormal triglycerides and abnormal HDL levels, 
individually has significant correlation with the age category, according to their p-value 
<0.01 level. 
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5.5.2 Distribution of Metabolic Syndrome Parameters among Sex Category 
SEX WC SBP DBP FBS TGL HDL 
Male 
N 78 78 78 78 78 78
Mean 93.63 135.18 85.97 109.95 159.40 37.35
SD 5.604 10.999 6.610 14.710 22.872 5.564
Female 
N 58 58 58 58 58 58
Mean 89.62 126.69 81.52 102.62 150.76 44.74
SD 4.344 11.079 7.002 9.814 20.371 6.186
Total 
N 136 136 136 136 136 136
Mean 91.92 131.56 84.07 106.82 155.71 40.50
SD 5.462 11.772 7.107 13.316 22.180 6.877
F – Value 20.490 19.696 14.379 10.806 5.203 53.404
p- Value 0.000* 0.000* 0.000* 0.001* 0.024** 0.000*
* Significant at 0.01 level 
** Significant at 0.05 level  
 Table 5.5.2 shows the distribution of individual metabolic syndrome parameters 
among the sex categories with their mean and standard deviation. All the metabolic 
syndrome parameters waist circumference, systolic blood pressure, diastolic blood 
pressure, fasting blood sugar, abnormal HDL levels, individually has significant 
correlation with the age category, according to their p-value <0.01 level and abnormal 
triglycerides have significant correlation with the age category, according to their p-
value <0.05 level. 
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5.5.3 Distribution of Parameters among MS Category by Modified NECP ATP III 
 
MS.BY. 
NECP. ATPIII AGE WC SBP DBP FBS TGL HDL 
Yes  
N 64 64 64 64 64 64 64
Mean 35.58 95.50 139.91 89.25 114.69 172.70 36.97
SD 2.984 4.704 7.932 5.595 13.509 16.898 6.907
No 
N 72 72 72 72 72 72 72
Mean 27.92 88.74 124.14 79.47 99.83 140.61 43.64
SD 3.931 3.907 9.437 4.759 8.362 13.805 5.133
Total 
N 136 136 136 136 136 136 136
Mean 32.60 91.92 131.56 84.07 106.82 155.71 40.50
SD 5.040 5.462 11.772 7.107 13.316 22.180 6.877
F - Value 165.525 83.825 109.736 121.250 60.855 148.347 41.422
p- Value 0.000* 0.000* 0.000* 0.000* 0.000* 0.000* 0.000*
* Significant at 0.01 level 
 
 Table 5.5.3 shows the distribution of parameters among metabolic syndrome 
category by NCEP ATP III Criteria with their mean and standard deviation. All the 
parameters waist circumference, systolic blood pressure, diastolic blood pressure, 
fasting blood sugar, abnormal triglycerides and abnormal HDL levels, individually has 
significant correlation with the metabolic syndrome category, according to their p-value 
<0.01 level. 
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5.5.4 Distribution of Parameters among MS Category by IDF 
MS.BY.IDF AGE WC SBP DBP FBS TGL HDL 
Yes  
N 61 61 61 61 61 61 61
Mean 35.76 95.7 140.33 89.31 115.11 171.59 37.11
SD 2.967 4.663 7.951 5.315 13.680 17.553 6.785
No 
N 75 75 75 75 75 75 75
Mean 28.21 88.84 124.43 79.81 100.08 142.80 43.25
SD 3.908 3.922 9.307 5.314 8.306 16.459 5.640
Total 
N 136 136 136 136 136 136 136
Mean 32.60 91.92 131.56 84.07 106.82 155.71 40.50
SD 5.040 5.462 11.772 7.107 13.316 22.180 6.877
F - Value 163.978 86.965 111.701 107.456 62.383 96.965 33.199
p - Value 0.000* 0.000* 0.000* 0.000* 0.000* 0.000* 0.000*
* Significant at 0.01 level 
 
Table 5.5.4 shows the distribution of parameters among metabolic syndrome 
category by IDF Criteria with their mean and standard deviation. All the parameters 
waist circumference, systolic blood pressure, diastolic blood pressure, fasting blood 
sugar, abnormal triglycerides and abnormal HDL levels, individually has significant 
correlation with the metabolic syndrome category, according to their p-value <0.01 
level. 
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5.6 Lp(a) AND OTHER PARAMETERS 
5.6.1 Lp(a) and Age, Sex, Religion Categories  
Factors Category Number Mean SD F- Value p- Value 
Age 
24 - 29 Years 43 21.3681 5.66707 
70.471 0.000* 30 - 34 Years 28 45.6282 14.11606 
35 - 39 Years 65 56.9342 19.49907 
Sex 
Male 78 46.2577 24.53144 
3.292 0.072 
Female 58 39.4662 16.81050 
Religion 
Hindu 82 43.8849 22.73297 
1.080 0.343 Christian 42 40.3057 18.83605 
Muslim  12 50.4783 24.40403 
* Significant at 0.01 level 
 
 In our study population, maximum amount of lipoprotein (a) is present in the 
age group of 35-39 years with the mean and standard deviation of 56.93 ± 19.49, 
followed by 30-34 years with the mean and standard deviation of 45.62 ± 14.11 and 
then 24-29 years with the mean and standard deviation of 21.36 ± 5.66. Amount of 
lipoprotein (a) among various age categories has significant correlation according to 
their p-value 0.000 (<0.01). In sex category, maximum amount of lipoprotein (a) is 
present in the males with the mean and standard deviation of 46.25 ± 24.53 compared 
to the females with the mean and standard deviation of 39.46 ± 16.81. Amount of 
lipoprotein (a) among sex category has no significant correlation according to their p-
value 0.072 (>0.05).In religion category, maximum amount of lipoprotein (a) is present 
in Muslims with the mean and standard deviation of 50.47 ± 24.40 followed by Hindus 
with the mean and standard deviation of 43.88 ± 23.73 and then Christians with the 
mean and standard deviation of 39.46 ± 16.81. Amount of lipoprotein (a) among 
religion category has no significant correlation according to their p-value 0.343 
(>0.05). 
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5.6.2 Lp(a) and Metabolic Syndrome   
 
MS Category  Number Mean SD F –Value p- Value 
Modified 
NECP ATP III 
Yes 64 58.5331 18.54920 
103.137 0.000* 
No 72 29.8753 14.27932 
IDF 
Yes 61 58.6128 18.60316 
90.136 0.000* 
No 75 30.9568 15.37194 
* Significant at 0.01 level 
 Amount of lipoprotein (a) is present in the metabolic syndrome category, by 
Modified NECP ATP III Criteria with the mean and standard deviation of 55.65 ± 
18.30 and IDF Criteria with the mean and standard deviation of 56.07 ± 18.10. 
Metabolic syndrome category by either Modified NECP ATP III Criteria or IDF 
Criteria has significant correlation with lipoprotein (a) according to their p-value 0.000 
(<0.01). 
 
5.7 CORRELATION OF PARAMETERS 
5.7.1 Correlation of Lp(a) with Other Parameters  
 Number Correlation Coefficient Significance 
AGE 136 0.751 0.000* 
WC 136 0.681 0.000* 
SBP 136 0.691 0.000* 
DBP 136 0.644 0.000* 
FBS 136 0.668 0.000* 
TGL 136 0.668 0.000* 
HDL 136 -0.636 0.000* 
* Correlation is significant at 0.01 level. 
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In our study, lipoprotein (a) with the age category has significant correlation 
according to the correlation coefficient 0.751 and p-value 0.000 (<0.01) and the 
lipoprotein (a) with the waist circumference has significant correlation according to the 
correlation coefficient 0.681 and p-value 0.000 (<0.01). Lipoprotein (a) with the 
systolic blood pressure has significant correlation according to the correlation 
coefficient 0.691 and p-value 0.000 (<0.01) and diastolic blood pressure has significant 
correlation according to the correlation coefficient 0.644 and p-value 0.000 
(<0.01).Lipoprotein (a) with the fasting blood sugar has significant correlation 
according to the correlation coefficient 0.668 and p-value 0.000 (<0.01) and also with 
the triglyceride level  has significant correlation according to the correlation coefficient 
0.668 and p-value 0.000 (<0.01). Finally, lipoprotein (a) with HDL cholesterol has 
significant negative correlation according to the correlation coefficient -0.636 and p-
value 0.000 (<0.01). 
 
5.7.2 Correlation of Age with Other Parameters  
 Number Correlation Coefficient Significance 
WC 136 0.579 0.000* 
SBP 136 0.723 0.000* 
DBP 136 0.627 0.000* 
FBS 136 0.624 0.000* 
TGL 136 0.628 0.000* 
HDL 136 -0.443 0.000* 
* Correlation is significant at 0.01 level.  
 
Table 5.7.2 shows correlation of age with metabolic syndrome parameters. Waist 
circumference, systolic blood pressure, diastolic blood pressure, fasting blood sugar 
and triglycerides have significant correlation with the age category according to their 
correlation coefficients (and p-values) respectively 0.579 (0.000) ,0.723 (0.000), 0.627 
(0.000), 0.624(0.000), 0.628 (0.000).HDL cholesterol has significant negative 
correlation with the age category according to their correlation coefficient -0.443 and p-
value 0.000. 
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5.7.3 Correlation of Other Parameters 
Control 
Variables 
Other 
Variables WC SBP DBP FBS TGL HDL 
AGE & 
Lp(a) 
WC 1.000 .406** .357** .401** .292** -.392**
SBP .406** 1.000 .573** .423** .318** -.416**
DBP .357** .573** 1.000 .297** .350** -.216*
FBS .401** .423** .297** 1.000 .165 -.233**
TGL .292** .318** .350** .165 1.000 -.247**
HDL -.392** -.416** -.216* -.233** -.247** 1.000
**. Correlation is significant at 0.01 level 
*. Correlation is significant at 0.05 level 
 
 Age and lipoprotein (a) is taking as control variables, correlation of other 
parameters of metabolic syndrome individually shows significant correlation except 
systolic and diastolic blood pressure. HDL has negative correlation with all other 
parameters of metabolic syndrome. 
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DISCUSSION 
Metabolic syndrome (MS), major components of which include central obesity, 
hypertriglyceridemia, low high-density lipoprotein levels, elevated BP and fasting 
hyperglycaemia has emerged as an important determinant of CV risk. Nowadays 
metabolic syndrome prevalence is increasing in the childhood and adolescent 
population. 
.  Applying the criteria of metabolic syndrome serves as a simple and 
inexpensive tool for identifying patients at high risk for diabetes mellitus and 
cardiovascular disease particularly those who do not fall into traditional risk categories. 
Though various diagnostic criteria for MS have been published, since Asian Indians 
have a tendency to develop metabolic abnormalities at a lower body mass index and 
waist circumference than other groups, conventional criteria may under estimate the 
prevalence of MS. This was also confirmed in our study; if abdominal obesity was 
considered an essential criterion (as recommended by the IDF guidelines) the 
prevalence of MS was underestimated (came down to 44.9% from 47.1%). Such a 
discrepancy has also been noted in previous studies and underscores the importance of 
using the modified South Asian guidelines to diagnose MS in the ethnic Indian 
population, (using obesity as an optional, and not an essential criterion, and the South 
Asian-specific waist circumference). 
 Shahbazian et al148 reported the prevalence of metabolic syndrome based on 
ATP III criteria was 22.8% in an urban population in south west of Iran. Jun Hyun et 
al149 reported the prevalence of metabolic syndrome based on ATP III criteria was 
38.8% in rural population of Korea. 
The ICMR task force collaborative study reported the prevalence of metabolic 
syndrome to be 30 per cent in urban areas of Delhi and 11 per cent in rural Haryana 
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using ATP-III criteria. Mishra et al2 reported 30 per cent prevalence among the urban 
slum population in Delhi. Ramchandran et al150 reported a prevalence of 41 per cent in 
urban area of Chennai using modified ATP-3 criteria among adults aged 20 to 75 yr. 
They also reported that prevalence was higher in women than men (46.5 vs. 36.4%) and 
in older people. Sarkar et al32 reported 40-50 per cent prevalence in Bhutia tribe, with 
no rural-urban difference. Among the Toto tribe, the rural community prevalence was 
low 4-9 per cent.  
Ramachandran et al150 reported prevalence of 46.5% while using a modified 
waist circumference for Indian women ≥ 85 cm (modified NCEP ATP-III criteria for 
Asian Indian).  Pandit vinodh et al151 reported 29.6 percent of metabolic syndrome by 
modified ATP-III criteria among urban adults of Kurnool, Karnataka. Thakur et al152 
reported 68.6 percent of metabolic syndrome by modified ATP-III criteria (63.6% by 
IDF criteria)   among adults in the northern hilly state of Himachal Pradesh. In our 
study, it was 47.1 % by modified NCEP ATP-III criteria and 44.9 % by IDF criteria. 
The differences may be attributed to the difference in study areas, and the 
different definitions of metabolic syndrome used. Thus our study reports higher 
prevalence of metabolic syndrome. It is reported that prevalence of metabolic 
syndrome may vary with ethnic background. Thus higher prevalence observed in our 
study suggests that Indian Asians may be more prone to metabolic syndrome compared 
to other parts of the world. However, certain reports from different parts of India has 
observed that even within the same ethnic population group significant differences in 
the prevalence metabolic syndrome may prevail. Thus it appears that apart from 
ethnicity several other characteristic features of given population may collectively 
contribute to the higher prevalence of metabolic syndrome. 
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Many factors including: age, weight, menopause in women, race, smoking, no 
alcohol consumption, low income economies, high carbohydrate intake, consumption 
of soft drink,  low physical activity, poor cardiovascular fitness, Genetic factors and 
antipsychotic drugs may playing a role in MS. 
According to waist circumference cut off criteria, Rajeev Gupta et al stuty153 
was 108cm (M) and 80cm (F). Dongfeng Gu et al154 and Pandit Vinodh et al151 studies 
used 90cm (M) and 80 cm (F) as a cut off criteria. We also used 90cm (M) and 80 cm 
(F) as a cut off criteria similar to above studies. Different studies uses different criteria, 
in this analysis, we have used the ATP III criteria, with a modification to the value for 
waist circumference (WC) that is more applicable to the Asian Indian population. The 
waist circumference criteria followed in this study is comparable with A.Ramachandran 
et al150, Dongfeng Gu et al154 and Pandit Vinodh et al151. 
G.P.Parale et al155 study shows 13.22% of males and 7.36% of females are 
affected by diabetes mellitus. Rajeev Gupta et al153 (16.9% males, 16.1% females), 
Pandit Vinodh et al151 (18.4% males, 11.2% females) also shows maximum numbers of 
males are affected by diabetes compared to females. However Sarkar et al32 study 
shows 20.7% males and 41.3% females, which is contradictory to other three studies. In 
our study males are mostly affected than females.  
The percentage of subjects with diabetes mellitus are high both in males and 
females compared to other studies and it shows a rising trend in the prevalence of 
diabetes. In our study, incidence of diabetes mellitus in males was higher than the 
females because women  mainly develop peripheral adiposity with gluteal fat 
accumulation, whereas men are more prone to development of central or android 
obesity. (However, concentrations of lipoproteins as well as body fat distribution in 
women shift to a male pattern after menopause). According to previous studies, obesity 
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and insulin resistance are closely linked, and obesity may precede development of 
insulin resistance. Insulin resistance subsequently leads to elevation in triglyceride, 
glucose level and blood pressure, and reduction of HDL-cholesterol levels. 
Shahbazian et al148 study (13.7% males & 16.9% females), Kamble et al156 
study (53.5% males & 54.2% females) shows females are maximum affected by 
hypertension compared to males. Pandit Vinodh et al151 (21.6% males & 18.4% 
females), Surana et al157 (75.1% males & 71.01% females) shows males are affected 
mostly by hypertension.  
 The percentage of hypertension in our study (52.6% males and 34.5% females) is 
similar to Kamble et al156 study in rural wartha, central India. Males are more affected by 
hypertension than the females because of android type obesity and smoking. Smoking 
leads to narrowing of blood vessels and increases the blood pressure. 
 Kamble et al156 study (33.5% in males & 26% in females), Shahbazian et al148 
study (47.8% in males & 34.2% in females), Surana et al157 study (58.32% in males & 
57.25% in females) show abnormal triglyceride levels more in males compared to 
females. Pandit Vinodh et al151 study shows the other way i.e abnormal triglyceride levels 
more in females (24.0% in females and 20.8% in males). However our study 
substantiates Kamble et al156, Shahbazian et al148 and Surana et al157 study results. The 
value of our study is similar to Surana et al study (53.8% in males and 37.9% in females). 
 Pandit Vinodh et al151 studies show decreased HDL levels 22.4% in males and 
20.8% in females. Here decreased HDL levels are more or less similar in males and 
females. The other studies show decreased HDL levels more in females compared to 
males. Shahbazian et al148 study shows decreased HDL 28.5% in males and 50.7% in 
females, Surana et al157 study shows 43.05% in males and 64.59% in females, and 
Kamble et al156 study shows 50% in males and 70.2% in females. Likewise our study 
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also shows HDL levels decreased more in females compared to males. The values are 
similar to Shahbazian et al148 study. 
Metabolic syndrome category by either Modified NECP ATP III Criteria or IDF 
Criteria has significant correlation with lipoprotein (a) according to their p-value 0.000 
(<0.01). Lipoprotein (a) and individual parameters of metabolic syndrome has also 
significant correlation according to their p-value (<0.01) levels. Among them HDL has 
negative correlation with lipoprotein (a). 
Subjects with MS have increased levels of Lp(a) compared to the normal 
subjects. Our result is similar to the study of Bermudez et al159 and Bozbas et al158. This 
association differs from the study done in older Japanese adults160 where Lp(a) and MS 
have no significant correlation. 
There are not much of studies explaining the relationship between individual 
components of MS and Lp(a) 163. Only few studies dealt about this relationship. In our 
study, every individual component of the MS has significant correlation with Lp(a) like 
Bermudez et al159 study. Our results differ from the study done by Candido et al164 in 
400 Brazilian individuals (here, no significant correlation between MS and Lp(a)).  
 In our population, age and sex has significant correlation with Lp(a).so, age  
also the main risk factor for presenting elevated Lp(a), similar to previous studies on 
Swedish subjects 166  and on Taiwanese population165. According to sex, males have 
higher Lp(a) levels than females similar to Kotani et al study160. 
One limitation of our study was that, this study was cross sectional that does not 
allow us to draw any causal interference. Therefore in the future large prospective 
studies should be used to confirm the association between above mentioned factors and 
metabolic syndrome. 
  
 
 
 
 
                    CONCLUSION 
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CONCLUSION  
In our study, prevalence of metabolic syndrome in younger population (24-39 
years) by Modified NCEP ATP III Criteria is 47.1%. Prevalence is maximum 76.9% at 
the age group of 35-39 years followed by 50% in the age group of 30-34 years and then 
0% in 24-29 years. Prevalence of metabolic syndrome with age category has significant 
correlation. According to gender, 47.4% males and 46.6% females were affected by 
metabolic syndrome. It has no significant correlation. 
Prevalence of metabolic syndrome in younger population (24-39 years) by IDF 
Criteria is 44.9%. Prevalence is maximum 73.8% at the age group of 35-39 years 
followed by 46.4% in the age group of 30-34 years and then 0% in 24-29 years. 
Prevalence of metabolic syndrome with age category has significant correlation. 
According to gender, 46.2% males and 43.1% females were affected by metabolic 
syndrome. It has no significant correlation. Lipoprotein (a) level is increased in the 
metabolic syndrome category by Modified NCEP ATP III Criteria and IDF Criteria. 
Lipoprotein (a) level has significant correlation with the metabolic syndrome according 
to their p values (<0.01). It has significantly correlated with the individual components 
of metabolic syndrome and age category also (p value <0.01). 
The significant increase in the prevalence of metabolic syndrome is the major 
risk factor for mainly coronary heart disease and diabetes mellitus. Health education 
and awareness among individuals about nutrition, physical exercise and maintenance of 
waist circumference from the younger age group is required to prevent major non-
communicable health disorders in the era of increasing life expectancy. Detection of 
one component of the metabolic syndrome should lead to the search for the other 
components and its management. 
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SUMMARY 
The metabolic syndrome is a multiplex risk factor for atherosclerotic 
cardiovascular disease. It consists of an abdominal obesity, atherogenic dyslipidemia, 
elevation of blood pressure and glucose, prothrombotic and proinflammatory states. 
The risk of ASCVD accompanying the MS is approximately doubled compared with an 
absence of the syndrome.  
The present study aims to know the prevalence of metabolic syndrome among 
younger population (24-39 years) and to study the relationship between Lipoprotein (a) 
and metabolic syndrome. 
We evaluated 136 patients and bystanders, who attended the medicine OPD of 
SMIMS. The following parameters were collected: age, gender, religion, waist 
circumference, blood pressure and fasting blood sugar, serum triglycerides and serum 
HDL.  
In our study, prevalence of metabolic syndrome in younger population (24-39 
years) by Modified NCEP ATP III Criteria is 47.1% and IDF Criteria is 44.9%.  
Lipoprotein (a) level is increased in the metabolic syndrome and it has significant 
correlation with the metabolic syndrome. It has significantly correlated even with the 
individual components of metabolic syndrome and age category also. 
The significant increase in the prevalence of MS is the major risk factor for 
mainly coronary heart disease and diabetes mellitus. Elevation of Lipoprotein (a) levels 
also main risk factor for coronary heart disease. Health education and awareness among 
individuals about nutrition, physical exercise and maintenance of waist circumference 
from the younger age group is required to prevent MS and also the CHD in future. 
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                       ANNEXURE  
 CONSENT FORM 
PART – II 
 The details of the study have been explained to me in writing and the details 
have been fully explained to me. I am aware that the results of the study may not be 
directly beneficial to me but will help in the advancement of medical sciences. I 
confirm that I have understood the study and had the opportunity to ask questions. I 
understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without the medical care that will 
normally be provided by the hospital being affected. I agree not to restrict the use of 
any data or results that arise from this study provided such a use is only for scientific 
purpose(s). I have been given an information sheet giving details of the study. I fully 
consent to participate in the study titled “Study of Lipoprotein(a) and biochemical 
parameters of metabolic syndrome among younger population”. I give consent for 
withdrawing blood (10ml) from my body for your study. 
Serial no/Reference no: 
Name of the Participant:    Address of the Participant: 
 
Contact number of the Participant: 
 
Signature/Thumb impression of the participant/Legal guardian: 
Witness 
1. 
2. 
Date: 
Place: Kulasekharam 
ANNEXURE I - CASE PROFORMA 
SREE MOOKAMBIKA INSTITUTE OF MEDICAL SCIENCES, 
KULASEKHARAM 
TITLE OF STUDY : Study of Lipoprotein(a)  and biochemical parameters of    
metabolic   syndrome among younger  population 
HOSPITAL NO : 
SERIAL NO  : 
DATE   : 
NAME  : 
AGE   : 
SEX   : 
ADDRESS & PHONE NO : 
BRIEF HISTORY  : 
GENERAL EXAMINATION: 
WAIST CIRCUMFERENCE: 
BLOOD PRESSURE 
      Systolic BP  :         
      Diastolic BP  :                                                                                  
INVESTIGATIONS  :  FBS,  
SERUM TRIGLYCERIDES, 
  SERUM HDL, 
LIPOPROTEIN(a).                    
                                                                                          
SIGNATURE OF INVESTIGATOR  
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1 RAM PRAKASH 24 1. MALE 1. HINDU 92 2. NO 120 80 2. NO 120 2. NO 122 38 28.6
2 RADHA 24 2. FEMALE 1. HINDU 82 2. NO 100 70 2. NO 94 2. NO 134 52 26.2
3 AUGUSTIN 24 1. MALE 2. CHRISTIAN 94 2. NO 126 80 2. NO 100 2. NO 140 44 21.2
4 PRADEEPKUMAR 24 1. MALE 1. HINDU 88 2. NO 118 80 2. NO 91 2. NO 142 45 24
5 KALPANA 24 2. FEMALE 1. HINDU 84 2. NO 118 70 2. NO 100 2. NO 137 39 22
6 AJAYAN 24 1. MALE 1. HINDU 86 2. NO 120 80 2. NO 98 2. NO 138 50 19.4
7 HUMAYOON 24 1. MALE 3. MUSLIM 84 2. NO 110 78 2. NO 100 2. NO 142 42 21.2
8 RAMYA 24 2. FEMALE 1. HINDU 78 2. NO 110 70 2. NO 96 2. NO 128 52 22.1
9 RAMESH 24 1. MALE 1. HINDU 88 2. NO 126 80 2. NO 98 2. NO 130 41 13.12
10 SREEKALA 24 2. FEMALE 1. HINDU 82 2. NO 116 70 2. NO 100 2. NO 117 52 16.83
11 VANITHARANI 24 2. FEMALE 2. CHRISTIAN 78 2. NO 110 70 2. NO 90 2. NO 132 54 18.6
12 SHAJI 25 1. MALE 2. CHRISTIAN 92 2. NO 130 80 2. NO 92 2. NO 130 40 22.2
13 SHAHAYARAJ 25 1. MALE 2. CHRISTIAN 88 2. NO 126 82 2. NO 96 2. NO 132 42 18.2
14 MONIKA 25 2. FEMALE 1. HINDU 82 2. NO 112 78 2. NO 92 2. NO 128 50 16.83
15 SUMAN 25 1. MALE 1. HINDU 94 2. NO 130 80 2. NO 94 2. NO 140 42 18.71
16 PADMA 25 2. FEMALE 1. HINDU 86 2. NO 118 70 2. NO 86 2. NO 118 46 16.12
17 VAISHANTH 25 1. MALE 1. HINDU 89 2. NO 120 82 2. NO 88 2. NO 132 48 18.4
18 RADHA 25 2. FEMALE 1. HINDU 88 2. NO 120 80 2. NO 90 2. NO 128 52 13.12
19 ANTONYJERSON 25 1. MALE 2. CHRISTIAN 90 2. NO 126 82 2. NO 100 2. NO 142 46 21.2
20 ADVIN 26 1. MALE 2. CHRISTIAN 85 2. NO 120 80 2. NO 84 2. NO 122 44 13.12
21 JEBA 26 2. FEMALE 2. CHRISTIAN 90 2. NO 118 82 2. NO 82 2. NO 118 48 18.71
22 MANOJ 26 1. MALE 1. HINDU 88 2. NO 126 80 2. NO 100 2. NO 140 42 26.2
23 RAMYA 26 2. FEMALE 1. HINDU 88 2. NO 110 70 2. NO 96 2. NO 124 52 16.73
24 JOSEPH 26 1. MALE 2. CHRISTIAN 92 2. NO 130 82 2. NO 102 2. NO 136 46 22.4
25 REJIN 27 1. MALE 2. CHRISTIAN 92 2. NO 122 80 2. NO 100 2. NO 134 38 24.2
26 LALITHA 27 2. FEMALE 1. HINDU 88 2. NO 108 72 2. NO 98 2. NO 128 48 16.43
27 PREETHI 27 2. FEMALE 1. HINDU 90 2. NO 110 70 2. NO 100 2. NO 140 46 18.71
28 AKSHAY 27 1. MALE 1. HINDU 88 2. NO 120 78 2. NO 96 2. NO 142 40 26.3
29 LATHA 27 2. FEMALE 1. HINDU 92 2. NO 112 78 2. NO 102 2. NO 132 39 22.1
30 BENRAJ 27 1. MALE 2. CHRISTIAN 86 2. NO 122 80 2. NO 88 2. NO 118 42 20.1
31 VIJAYAKUMAR 27 1. MALE 1. HINDU 88 2. NO 130 80 2. NO 102 2. NO 122 44 23.2
32 AHAMED 28 1. MALE 3. MUSLIM 94 2. NO 130 80 2. NO 104 2. NO 144 42 22.1
33 VINOTHJOY 28 1. MALE 2. CHRISTIAN 88 2. NO 130 82 2. NO 98 2. NO 122 40 16.4
34 ABDULRASHAK 28 1. MALE 3. MUSLIM 86 2. NO 122 80 2. NO 96 2. NO 130 38 18.2
35 RASHIKA 28 2. FEMALE 1. HINDU 90 2. NO 120 78 2. NO 90 2. NO 146 48 28.2
36 BRYSONPAUL 28 1. MALE 2. CHRISTIAN 84 2. NO 116 78 2. NO 99 2. NO 142 40 13.4
37 ANUJA 28 2. FEMALE 1. HINDU 88 2. NO 110 78 2. NO 92 2. NO 146 46 14.7
38 RAMKUMAR 29 1. MALE 1. HINDU 92 2. NO 130 80 2. NO 100 2. NO 148 40 32.4
39 ARTHY 29 2. FEMALE 1. HINDU 86 2. NO 110 70 2. NO 86 2. NO 132 48 28.6
40 RASHEER 29 1. MALE 3. MUSLIM 94 2. NO 130 82 2. NO 106 2. NO 162 36 36.3
41 MANIKANDAN 29 1. MALE 1. HINDU 94 2. NO 124 84 2. NO 108 2. NO 156 38 34.2
42 JOHN 29 1. MALE 2. CHRISTIAN 88 2. NO 120 80 2. NO 92 2. NO 130 42 18.3
MASTER CHART
43 ABINAYA 29 2. FEMALE 1. HINDU 88 2. NO 120 80 2. NO 96 2. NO 112 52 29.8
44 RAJAN 30 1. MALE 1. HINDU 88 2. NO 126 80 2. NO 104 2. NO 166 42 30.3
45 RAMYA 30 2. FEMALE 1. HINDU 82 2. NO 120 80 2. NO 96 2. NO 160 48 29.8
46 NIBINKUMAR 30 1. MALE 1. HINDU 88 2. NO 126 80 2. NO 98 2. NO 152 38 29.4
47 AMALRAJ 30 1. MALE 2. CHRISTIAN 98 1. YES 140 90 1. YES 118 2. NO 186 38 36.4
48 SATHYAMMAL 30 2. FEMALE 1. HINDU 90 2. NO 130 80 2. NO 100 2. NO 160 42 32.3
49 RIYAS 30 1. MALE 3. MUSLIM 104 2. NO 140 90 1. YES 120 2. NO 167 36 58.5
50 VINUJA 30 2. FEMALE 1. HINDU 88 2. NO 120 80 2. NO 102 2. NO 144 48 31.4
51 PAULRAJ 31 1. MALE 2. CHRISTIAN 86 2. NO 130 80 2. NO 98 2. NO 148 38 33.1
52 RAMCHANDHAR 31 1. MALE 1. HINDU 90 2. NO 140 80 1. YES 110 2. NO 172 42 42.4
53 JENIFER 31 2. FEMALE 2. CHRISTIAN 86 2. NO 130 80 1. YES 104 2. NO 148 48 28.3
54 BRITTO 31 1. MALE 2. CHRISTIAN 94 2. NO 130 80 2. NO 104 2. NO 166 38 46.4
55 KOCHURANI 31 2. FEMALE 1. HINDU 86 2. NO 126 86 2. NO 98 2. NO 162 46 52.3
56 ALEX 31 1. MALE 2. CHRISTIAN 94 1. YES 140 100 2. NO 106 2. NO 188 38 66.1
57 SREENIVAS 32 1. MALE 1. HINDU 90 2. NO 140 90 1. YES 110 2. NO 166 28 41.3
58 NAGARAJ 32 1. MALE 1. HINDU 88 2. NO 130 80 2. NO 106 2. NO 152 36 31.4
59 LISHIKA 32 2. FEMALE 2. CHRISTIAN 86 2. NO 130 80 2. NO 100 2. NO 126 48 46.2
60 RIYAZAHAMED 32 1. MALE 3. MUSLIM 98 1. YES 140 100 1. YES 120 2. NO 204 38 54.3
61 PARVATHI 34 2. FEMALE 1. HINDU 86 2. NO 130 80 2. NO 98 2. NO 136 52 31.3
62 KRISHNAN 34 1. MALE 1. HINDU 92 2. NO 130 80 2. NO 104 1. YES 168 38 58.5
63 HARISH 34 1. MALE 1. HINDU 104 1. YES 140 100 1. YES 122 2. NO 184 28 69.36
64 CHANDRAMANI 34 2. FEMALE 1. HINDU 92 2. NO 126 80 1. YES 118 2. NO 144 44 52.31
65 SARADHA 34 2. FEMALE 1. HINDU 94 2. NO 130 80 2. NO 100 2. NO 160 38 55.13
66 LAKSHMI 34 2. FEMALE 1. HINDU 90 2. NO 130 80 2. NO 96 2. NO 162 36 41.13
67 MURALI 34 1. MALE 1. HINDU 94 2. NO 140 90 1. YES 112 2. NO 166 40 36.12
68 VISHWANATH 34 1. MALE 1. HINDU 96 1. YES 130 86 2. NO 104 1. YES 178 38 55.11
69 MINATHULMUFITHA 34 2. FEMALE 3. MUSLIM 90 2. NO 126 84 2. NO 100 2. NO 172 46 58.5
70 LAIDON 34 1. MALE 2. CHRISTIAN 102 1. YES 150 100 2. NO 120 1. YES 196 36 82.1
71 MARYPAULIN 34 2. FEMALE 2. CHRISTIAN 88 2. NO 130 80 1. YES 110 2. NO 156 48 48.13
72 VISHWANATHAN 35 1. MALE 1. HINDU 88 2. NO 130 80 2. NO 98 2. NO 144 42 29.13
73 SUBRAMANIYAM 35 1. MALE 1. HINDU 91 2. NO 130 80 2. NO 102 2. NO 156 38 36.73
74 CHANDRAKUMAR 35 1. MALE 1. HINDU 96 1. YES 150 90 1. YES 110 2. NO 166 40 42.53
75 CHANDRA 35 2. FEMALE 1. HINDU 92 2. NO 146 92 2. NO 108 2. NO 172 36 55.41
76 SAHAYARANI 35 2. FEMALE 2. CHRISTIAN 94 2. NO 130 80 2. NO 106 1. YES 188 26 66.52
77 RAHAV 35 1. MALE 1. HINDU 90 2. NO 140 90 2. NO 102 2. NO 162 36 36.6
78 MINI 35 2. FEMALE 2. CHRISTIAN 90 2. NO 150 90 2. NO 104 2. NO 170 45 42.51
79 JOSEPH 35 1. MALE 2. CHRISTIAN 102 1. YES 150 100 1. YES 118 1. YES 204 28 52.3
80 MARYARULPRIYA 35 2. FEMALE 2. CHRISTIAN 94 2. NO 140 90 1. YES 112 2. NO 192 44 40.21
81 BINDHU 35 2. FEMALE 1. HINDU 92 1. YES 140 80 1. YES 112 2. NO 188 46 32.12
82 JAINSON 35 1. MALE 2. CHRISTIAN 90 2. NO 130 80 2. NO 96 1. YES 146 38 30.12
83 SHEELA 35 2. FEMALE 2. CHRISTIAN 94 2. NO 126 84 2. NO 100 2. NO 182 48 55.52
84 BRAVIANJOHN 35 1. MALE 2. CHRISTIAN 104 1. YES 140 90 1. YES 122 2. NO 196 38 46.13
85 RAJESH 36 1. MALE 1. HINDU 92 1. YES 146 86 1. YES 110 2. NO 138 42 33.13
86 LINDA 36 2. FEMALE 2. CHRISTIAN 88 2. NO 130 90 2. NO 98 2. NO 148 52 29.36
87 SHIVA 36 1. MALE 1. HINDU 92 1. YES 140 90 2. NO 106 1. YES 166 38 32.13
88 YAMUNA 36 2. FEMALE 1. HINDU 90 2. NO 140 90 2. NO 108 2. NO 138 50 36.72
89 ALENKIRUBA 36 1. MALE 2. CHRISTIAN 94 2. NO 130 86 1. YES 112 2. NO 162 36 40.12
90 PRASATH 36 1. MALE 1. HINDU 92 2. NO 140 80 2. NO 106 2. NO 160 32 72.34
91 ANDAL 36 2. FEMALE 1. HINDU 86 2. NO 130 90 2. NO 100 2. NO 152 48 52.15
92 VISHNU 36 1. MALE 1. HINDU 94 1. YES 150 90 1. YES 108 2. NO 172 26 66.72
93 SHANKAR 36 1. MALE 1. HINDU 88 2. NO 140 100 2. NO 110 2. NO 190 28 82.13
94 AMUDHA 37 2. FEMALE 1. HINDU 92 2. NO 140 90 1. YES 110 2. NO 142 44 46.81
95 KARTHIKEYAN 37 1. MALE 1. HINDU 104 1. YES 140 90 1. YES 122 1. YES 164 28 90.13
96 SOWNDHARYA 37 2. FEMALE 1. HINDU 90 2. NO 130 90 2. NO 102 2. NO 160 35 66.41
97 SUBRAMANIYAM 37 1. MALE 1. HINDU 102 1. YES 150 90 1. YES 140 1. YES 176 26 88.02
98 RADHIKA 37 2. FEMALE 2. CHRISTIAN 94 2. NO 128 82 2. NO 108 2. NO 152 38 70.12
99 SURESH 37 1. MALE 1. HINDU 98 1. YES 140 86 2. NO 106 2. NO 154 38 62.43
100 SHAKIN 37 1. MALE 3. MUSLIM 96 2. NO 126 76 2. NO 108 2. NO 136 40 64.13
101 PRAVEEN 37 1. MALE 1. HINDU 100 2. NO 150 90 1. YES 130 1. YES 160 25 88.5
102 KANMANI 37 2. FEMALE 1. HINDU 96 1. YES 130 90 2. NO 102 2. NO 166 44 62.2
103 REVANDH 37 1. MALE 1. HINDU 92 2. NO 130 90 2. NO 110 2. NO 144 39 64.31
104 NISHANDH 37 1. MALE 1. HINDU 102 1. YES 150 90 1. YES 142 1. YES 196 28 87.13
105 LEKHA 37 2. FEMALE 1. HINDU 94 2. NO 130 80 2. NO 100 2. NO 172 48 55.5
106 LINGAMMAL 37 2. FEMALE 2. CHRISTIAN 92 2. NO 130 80 1. YES 102 1. YES 180 46 44.24
107 RAJASEKAR 37 1. MALE 2. CHRISTIAN 92 2. NO 140 90 2. NO 110 2. NO 188 38 36.13
108 MYTHILI 38 2. FEMALE 1. HINDU 90 2. NO 126 84 2. NO 106 2. NO 148 38 66.14
109 MIMMYRAJ 38 2. FEMALE 2. CHRISTIAN 92 2. NO 130 80 2. NO 102 2. NO 152 44 64.43
110 ABILESH 38 1. MALE 1. HINDU 102 1. YES 150 90 1. YES 118 1. YES 166 26 86.24
111 SAJEETHA 38 2. FEMALE 2. CHRISTIAN 94 2. NO 130 90 1. YES 128 2. NO 168 38 46.31
112 SUJI 38 2. FEMALE 1. HINDU 90 2. NO 130 90 2. NO 96 2. NO 140 40 32.16
113 ROBINSON 38 1. MALE 2. CHRISTIAN 100 1. YES 150 90 1. YES 120 1. YES 172 28 55.8
114 PREMA 38 2. FEMALE 1. HINDU 92 1. YES 140 90 2. NO 102 2. NO 144 42 40.42
115 JOHNSON 38 1. MALE 2. CHRISTIAN 100 1. YES 150 90 1. YES 120 1. YES 176 34 52.15
116 ROMY 38 2. FEMALE 2. CHRISTIAN 98 2. NO 140 90 2. NO 114 2. NO 158 38 42.1
117 JEYARAM 38 1. MALE 1. HINDU 101 1. YES 140 90 2. NO 116 1. YES 168 32 90.12
118 DHINESH 38 1. MALE 1. HINDU 103 2. NO 140 90 2. NO 118 2. NO 184 30 86.13
119 SAHAYAMARI 38 2. FEMALE 2. CHRISTIAN 96 2. NO 150 86 1. YES 130 2. NO 170 25 66.3
120 SASIKUMAR 38 1. MALE 1. HINDU 98 1. YES 146 86 1. YES 122 2. NO 202 34 55.43
121 DIVYA 38 2. FEMALE 1. HINDU 92 2. NO 130 90 2. NO 108 2. NO 192 48 42.14
122 VINUJA 38 2. FEMALE 2. CHRISTIAN 96 2. NO 130 80 2. NO 106 2. NO 188 42 36.2
123 ANEER 38 1. MALE 3. MUSLIM 98 2. NO 140 90 1. YES 122 2. NO 166 36 32.42
124 DEVI 38 2. FEMALE 1. HINDU 94 2. NO 126 76 2. NO 104 2. NO 144 38 44.42
125 ANWAR 38 1. MALE 3. MUSLIM 102 1. YES 150 90 1. YES 114 1. YES 186 34 84.61
126 SATHEESH 39 1. MALE 1. HINDU 100 2. NO 140 90 1. YES 140 2. NO 152 39 64.59
127 PUSHPARAJAN 39 1. MALE 1. HINDU 104 1. YES 150 100 1. YES 170 1. YES 166 36 90.91
128 SHAJI 39 1. MALE 2. CHRISTIAN 92 1. YES 160 90 1. YES 130 2. NO 156 38 69.36
129 SREJITH 39 1. MALE 1. HINDU 94 2. NO 140 100 1. YES 136 2. NO 176 40 70.13
130 JEBA 39 2. FEMALE 2. CHRISTIAN 92 1. YES 140 90 2. NO 128 1. YES 166 38 72.15
131 KAJAMYTHEEN 39 1. MALE 3. MUSLIM 92 1. YES 160 90 1. YES 144 2. NO 186 36 64.73
132 SUJI 39 2. FEMALE 1. HINDU 90 2. NO 126 76 2. NO 118 2. NO 146 50 29.31
133 ARAVINDH 39 1. MALE 1. HINDU 92 1. YES 150 90 1. YES 122 2. NO 204 26 90
134 MARIYMMAL 39 2. FEMALE 1. HINDU 92 1. YES 140 90 2. NO 116 1. YES 144 48 36.3
135 AJEEN 39 1. MALE 3. MUSLIM 96 1. YES 140 90 2. NO 108 1. YES 196 38 90.75
136 LEKHA 39 2. FEMALE 1. HINDU 94 2. NO 140 92 2. NO 110 2. NO 152 48 62.28
